var title_f16_30_16864="Fetal pyelectasis bilateral";
var content_f16_30_16864=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bilateral pyelectasis measuring 4 mm on each side",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tulin Ozcan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_30_16864=[""].join("\n");
var outline_f16_30_16864=null;
var title_f16_30_16865="Naftidrofuryl: International drug information";
var content_f16_30_16865=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Naftidrofuryl: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1979602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Artocoron (DE);",
"     </li>",
"     <li>",
"      Azunaftil (DE);",
"     </li>",
"     <li>",
"      Di-Actane (FR);",
"     </li>",
"     <li>",
"      Dusodril (AT, CZ, DE, HR);",
"     </li>",
"     <li>",
"      Esdedril (IT);",
"     </li>",
"     <li>",
"      Gevatran (FR);",
"     </li>",
"     <li>",
"      Iridus (AR);",
"     </li>",
"     <li>",
"      Iridux (BR);",
"     </li>",
"     <li>",
"      Iridux F200 (BR);",
"     </li>",
"     <li>",
"      Luctor (DE);",
"     </li>",
"     <li>",
"      Nafrolen (CY);",
"     </li>",
"     <li>",
"      nafti von ct (DE);",
"     </li>",
"     <li>",
"      Nafti-Puren (DE);",
"     </li>",
"     <li>",
"      Nafti-ratiopharm (DE);",
"     </li>",
"     <li>",
"      Naftilong (DE, HU, LU);",
"     </li>",
"     <li>",
"      Naftilux (FR);",
"     </li>",
"     <li>",
"      Naftisol (AT);",
"     </li>",
"     <li>",
"      Naftodril (AT);",
"     </li>",
"     <li>",
"      Praxilene (BE, CH, ES, FR, GB, IE, IT, LU, PT);",
"     </li>",
"     <li>",
"      Sodipryl (CH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1979595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Naftidrofuryl Oxalate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vasodilator",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of peripheral and cerebral vascular disorders",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cerebral vascular disorders: 100 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peripheral vascular disorders: 100-200 mg 3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Capsule: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Tablet: 200 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10419 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-2BDF7BB03E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_30_16865=[""].join("\n");
var outline_f16_30_16865=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979602\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979595\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979597\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979600\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979596\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821101\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979599\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10419\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10419|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_30_16866="Barretts methylene magnify";
var content_f16_30_16866=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Barrett's esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic image of specialized intestinal metaplasia in Barrett's esophagus with a tubular pit pattern by methylene blue high magnification chromoendoscopy (Olympus 240 Z, magnified 135x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marcia I Canto, MD, MHS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_30_16866=[""].join("\n");
var outline_f16_30_16866=null;
var title_f16_30_16867="Carbamide peroxide: Drug information";
var content_f16_30_16867=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carbamide peroxide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/43/22196?source=see_link\">",
"    see \"Carbamide peroxide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/30/41442?source=see_link\">",
"    see \"Carbamide peroxide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F145723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Auraphene B&reg; [OTC];",
"     </li>",
"     <li>",
"      Auro&reg; [OTC];",
"     </li>",
"     <li>",
"      Cankaid&reg; [OTC];",
"     </li>",
"     <li>",
"      Debrox&reg; [OTC];",
"     </li>",
"     <li>",
"      E-R-O&reg; [OTC];",
"     </li>",
"     <li>",
"      Gly-Oxide&reg; [OTC];",
"     </li>",
"     <li>",
"      Murine&reg; Ear Wax Removal Kit [OTC];",
"     </li>",
"     <li>",
"      Murine&reg; Ear [OTC];",
"     </li>",
"     <li>",
"      Otix&reg; [OTC];",
"     </li>",
"     <li>",
"      Wax Away [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F145732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-inflammatory, Locally Applied;",
"     </li>",
"     <li>",
"      Otic Agent, Cerumenolytic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F145724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Minor inflammation of gums, oral mucosal surfaces, and lips:",
"     </b>",
"     Topical: Oral solution (should not be used for &gt;7 days): Apply several drops undiluted on affected area 4 times/day after meals and at bedtime; expectorate after 2-3 minutes",
"     <b>",
"      or",
"     </b>",
"     place 10 drops onto tongue, mix with saliva, swish for several minutes, expectorate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ear wax removal:",
"     </b>",
"     Otic: Tilt head sideways and instill 5-10 drops twice daily up to 4 days, tip of applicator should not enter ear canal; keep drops in ear for several minutes by keeping head tilted and placing cotton in ear",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F145729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/30/41442?source=see_link\">",
"      see \"Carbamide peroxide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Relief of minor inflammation of gums, oral mucosal surfaces, and lips:",
"     </b>",
"     Topical: Children &ge;2 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ear wax removal:",
"     </b>",
"     Otic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &lt;12 years:",
"     </i>",
"     Tilt head sideways and individualize the dose according to patient size; 3 drops (range: 1-5 drops) twice daily for up to 4 days, tip of applicator should not enter ear canal. Keep drops in ear for several minutes by keeping head tilted and placing cotton in ear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &ge;12 years:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F145725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F145714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral: 10% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cankaid&reg;: 10% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gly-Oxide&reg;: 10% (15 mL, 60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, otic [drops]: 6.5% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Auraphene B&reg;: 6.5% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Auro&reg;: 6.5% (22.2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Debrox&reg;: 6.5% (15 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E-R-O&reg;: 6.5% (15 mL) [ethanol free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Murine&reg; Ear: 6.5% (15 mL) [contains ethanol 6.3%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Murine&reg; Ear Wax Removal Kit: 6.5% (15 mL) [contains ethanol 6.3%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otix&reg;: 6.5% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Wax Away: 6.5% (15 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F145700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F145715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of minor inflammation of gums, oral mucosal surfaces, and lips including canker sores and dental irritation; emulsify and disperse ear wax",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F145730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Irritation, redness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Superinfection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F145718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to carbamide peroxide or any component of the formulation; otic preparation should not be used in patients with a perforated tympanic membrane; ear drainage, ear pain, or rash in the ear",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F145704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral: With prolonged use of oral carbamide peroxide, there is a potential for overgrowth of opportunistic organisms, damage to periodontal tissues, and delayed wound healing; should not be used for longer than 7 days. Not for OTC use in children &lt;2 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Otic: Do not use if ear drainage or discharge, ear pain, irritation, or rash in ear. Should not be used for longer than 4 days. Not for OTC use in children &lt;12 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F145708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Orajel Perioseptic Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15% (13.3 mL): $3.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Auro Eardrops Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.5% (15 mL): $4.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cankaid Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (15 mL): $9.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Debrox Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.5% (15 mL): $4.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (E-R-O Ear Drops Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.5% (15 mL): $2.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (E-R-O Ear Wax Removal System Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.5% (15 mL): $3.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ear Wax Drops Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.5% (15 mL): $2.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Gly-Oxide Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (15 mL): $5.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Murine Ear Wax Removal System Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.5% (15 mL): $5.23",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Blanc-Dient (AR);",
"     </li>",
"     <li>",
"      Earclear (NZ)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F145703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Carbamide peroxide releases hydrogen peroxide which serves as a source of nascent oxygen upon contact with catalase; deodorant action is probably due to inhibition of odor-causing bacteria; softens impacted cerumen due to its foaming action",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F145717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: ~24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8841 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_30_16867=[""].join("\n");
var outline_f16_30_16867=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145723\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145732\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145724\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145729\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145725\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145714\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145700\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145715\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145730\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145718\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145704\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298957\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145708\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524399\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038549\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145703\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145717\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8841\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8841|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/43/22196?source=related_link\">",
"      Carbamide peroxide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/30/41442?source=related_link\">",
"      Carbamide peroxide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_30_16868="Semilobar holoprosencephaly";
var content_f16_30_16868=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Semilobar holoprosencephaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     T: thalamus.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_30_16868=[""].join("\n");
var outline_f16_30_16868=null;
var title_f16_30_16869="Lurasidone: Patient drug information";
var content_f16_30_16869=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lurasidone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/1/15383?source=see_link\">",
"     see \"Lurasidone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10946844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Latuda&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F15251999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Latuda&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F11422238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700570",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a higher chance of death in older adults who take this drug for mental problems caused by dementia. Most of the deaths were linked to heart disease or infection. This drug is not approved to treat mental problems caused by dementia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F11422239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat schizophrenia. It may take 6 weeks to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F11422225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3008540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lurasidone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F11422227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697190",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have breast cancer, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a family history of high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697268",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high cholesterol or triglyceride levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Parkinson's disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are overweight, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F11422406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals and good mouth care may help. Older children may suck hard, sugar-free candy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood sugar. This most often goes back to normal when drug is stopped.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F11422229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F11422405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F11422226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F11422407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F11422230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16086 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-C2273CD5CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_30_16869=[""].join("\n");
var outline_f16_30_16869=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10946844\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15251999\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11422238\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11422239\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11422225\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11422227\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11422406\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11422229\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11422405\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11422226\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11422407\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11422230\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/1/15383?source=related_link\">",
"      Lurasidone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_30_16870="Aluminum hydroxide and magnesium carbonate: Drug information";
var content_f16_30_16870=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aluminum hydroxide and magnesium carbonate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/48/17156?source=see_link\">",
"    see \"Aluminum hydroxide and magnesium carbonate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Acid Gone Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Acid Gone [OTC];",
"     </li>",
"     <li>",
"      Gaviscon&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Gaviscon&reg; Liquid [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F132599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antacid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F132592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dyspepsia, gastric acidity: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Liquid:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gaviscon&reg; Regular Strength: 15-30 mL 4 times/day after meals and at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gaviscon&reg; Extra Strength: 15-30 mL 4 times/day after meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Tablet",
"     </i>",
"     (Gaviscon&reg; Extra Strength): Chew 2-4 tablets 4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F132593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F132594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aluminum and/or magnesium may accumulate in renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F132585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acid Gone: Aluminum hydroxide 31.7 mg and magnesium carbonate 119.3 mg per 5 mL (360 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gaviscon&reg;: Aluminum hydroxide 31.7 mg and magnesium carbonate 119.3 mg per 5 mL (355 mL) [contains sodium 0.57 mEq/5 mL and benzyl alcohol; cool mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gaviscon&reg; Extra Strength: Aluminum hydroxide 84.6 mg and magnesium carbonate 79.1 mg per 5 mL (355 mL) [contains sodium 0.9 mEq/5 mL and benzyl alcohol; cool mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acid Gone Extra Strength: Aluminum hydroxide 160 mg and magnesium carbonate 105 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gaviscon&reg; Extra Strength: Aluminum hydroxide 160 mg and magnesium carbonate 105 mg [contains sodium 19 mg/tablet (1.3 mEq/tablet); cherry and original flavors]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F132575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9405834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer 1-3 hours after meals with water, milk or juice.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F132586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of symptoms associated with gastric acidity",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F11347389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Remegel [Netherlands] may be confused with Renagel brand name for sevelamer [U.S., Canada, and multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Remegel: Brand name for aluminum hydroxide and magnesium carbonate [Netherlands], but also the brand name for calcium carbonate [Great Britain, Hungary, and Ireland]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F132597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypermagnesemia, aluminum intoxication (prolonged use and concomitant renal failure), hypophosphatemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Osteomalacia",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F132581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Antacids may decrease the serum concentration of ACE Inhibitors.  Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Enalaprilat; Ramipril.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Antacids may decrease the absorption of Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Antacids may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antacids may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Antacids may decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Antacids may decrease the absorption of Atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Antacids may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the cation exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of CPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Aluminum Hydroxide. More specifically, concomitant use of these agents  may increase the risk for intestinal obstruction. Management: Monitor for signs/symptoms of intestinal obstruction with concomitant use of calcium polystyrene sulfonate and aluminum hydroxide. Adequate fluid intake, laxative use, alternative antacid agents, and/or limiting duration of therapy may help reduce risks.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Antacids may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management:  Consider administering antacids and cefuroxime at least 2 hours apart.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Aluminum Hydroxide may decrease the serum concentration of Chenodiol.  Management: Consider administration of chenodiol 2 hours before or 6 hours after aluminum-containing antacid products to prevent adsorption in the gastrointestinal tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citric Acid Derivatives: May increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Antacids may decrease the absorption of Dasatinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Aluminum Hydroxide may diminish the therapeutic effect of Deferasirox.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Antacids may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Antacids may increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Aluminum Hydroxide may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., aluminum-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir.  Management: Separate administration of antacids and the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product by at least 2 hours in order to minimize the risk for an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethambutol: Aluminum Hydroxide may decrease the absorption of Ethambutol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Antacids may decrease the serum concentration of Fexofenadine.  Management: No specific recommendations concerning the time required between their administration are provided. Separate administration of each agent by as much time as possible to decrease the risk of an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gabapentin: Antacids may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Antacids may decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Antacids may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Antacids may decrease the absorption of Isoniazid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Antacids may decrease the serum concentration of Itraconazole.  Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Aluminum Hydroxide may decrease the serum concentration of Levothyroxine.  Management: Separate administration of oral levothyroxine and aluminum hydroxide by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Antacids may diminish the therapeutic effect of Methenamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antacids may increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Misoprostol: Antacids may enhance the adverse/toxic effect of Misoprostol. More specifically, concomitant use with magnesium-containing antacids may increase the risk of diarrhea.  Management: Avoid concomitant use of misoprostol and magnesium-containing antacids. In patients requiring antacid therapy, employ magnesium-free preparations. Monitor for increased adverse effects (e.g., diarrhea, dehydration).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Aluminum Hydroxide. Management: In patients with severe renal dysfunction, consider avoiding this combination of agents.  Administering agents at least 2 hours apart may help minimize the interaction(s).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Antacids may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, antacids may decrease the absorption of orally administered iron.  Management: Separate dosing of oral iron-containing multivitamin preparations and antacids by as much time as possible in order to minimize impact on therapeutic efficacy of the iron preparation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Antacids may decrease the absorption of Mycophenolate.  Management: Separate doses of mycophenolate and antacids by at least 2 hours. Monitor for reduced effects of mycophenolate if taken concomitant with antacids.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Antacids may decrease the serum concentration of PenicillAMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Antacids may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Antacids may decrease the absorption of Protease Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antacids may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Antacids may decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Antacids may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of SPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Aluminum Hydroxide. More specifically, concomitant use of these agents  may increase the risk for intestinal obstruction. Management: Monitor for signs/symptoms of intestinal obstruction with concomitant use of calcium polystyrene sulfonate and aluminum hydroxide. Adequate fluid intake, laxative use, alternative antacid agents, and/or limiting duration of therapy may help reduce risks.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Aluminum Hydroxide may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and aluminum hydroxide by at least 2 hours whenever possible in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Antacids may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Antacids may decrease the absorption of Trientine.  Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Aluminum Hydroxide may decrease the serum concentration of Ursodiol.  Management: Consider administration of ursodiol 2 hours before or 6 hours after aluminum-containing antacid products to prevent adsorption in the gastrointestinal tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Antacids may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: May increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14286990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Most aluminum- and magnesium-containing antacids are considered low risk during pregnancy (Mahadevan, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14286991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Most aluminum- and magnesium-containing antacids are considered low risk in nursing women (Mahadevan, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F132588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken 1-3 hours after meals with water, milk or juice. Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Acid Gone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160-105 mg (100): $5.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Gaviscon Extra Relief Formula Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160-105 mg (30): $3.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Gaviscon Extra Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160-105 mg (100): $8.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Acid Gone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     95-358 mg/15 mL (355 mL): $5.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Gaviscon Extra Relief Formula Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     508-475 mg/10 mL (355 mL): $7.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Gaviscon Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     95-358 mg/15 mL (355 mL): $6.72",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Mahadevan U and Kane S, \"American Gastroenterological Association Institute Medical Position Statement on the Use of Gastrointestinal Medications in Pregnancy,\"",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 131(1):278-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16870/abstract-text/16831610/pubmed\" id=\"16831610\" target=\"_blank\">",
"        16831610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8613 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-0E8BE10A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_30_16870=[""].join("\n");
var outline_f16_30_16870=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132590\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132599\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132592\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132593\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132594\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132585\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132575\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9405834\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132586\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11347389\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132597\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298722\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132581\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286990\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286991\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132588\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322978\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8613\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8613|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/48/17156?source=related_link\">",
"      Aluminum hydroxide and magnesium carbonate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_30_16871="Nonsmall cell lung ca survival by TNM gp";
var content_f16_30_16871=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 627px\">",
"   <div class=\"ttl\">",
"    Overall survival by TNM grouping, non-small cell lung cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 607px; height: 491px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Overall survival, expressed as median survival time (MST) and five-year survival, using the sixth edition of TNM staging system by (A) clinical stage and (B) pathologic stage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2:706. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_30_16871=[""].join("\n");
var outline_f16_30_16871=null;
var title_f16_30_16872="Fosinopril: Drug information";
var content_f16_30_16872=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fosinopril: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/39/15989?source=see_link\">",
"    see \"Fosinopril: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/41/42647?source=see_link\">",
"    see \"Fosinopril: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F174408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Fosinopril&reg;;",
"     </li>",
"     <li>",
"      Jamp-Fosinopril;",
"     </li>",
"     <li>",
"      Monopril&reg;;",
"     </li>",
"     <li>",
"      Mylan-Fosinopril;",
"     </li>",
"     <li>",
"      PMS-Fosinopril;",
"     </li>",
"     <li>",
"      RAN&trade;-Fosinopril;",
"     </li>",
"     <li>",
"      Riva-Fosinopril;",
"     </li>",
"     <li>",
"      Teva-Fosinopril",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F174445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F174411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heart failure:",
"     </b>",
"     Oral: Initial: 10 mg/day (5 mg if renal dysfunction present) and increase, as needed, to a maximum of 40 mg once daily over several weeks. Usual dose: 20-40 mg/day. If hypotension, orthostasis, or azotemia occurs during titration, consider decreasing concomitant diuretic dose, if any.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 10 mg/day; increase to a maximum dose of 80 mg/day. Most patients are maintained on 20-40 mg/day. May need to divide the dose into two if trough effect is inadequate. Discontinue the diuretic, if possible 2-3 days before initiation of therapy. Resume diuretic therapy carefully, if needed.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F174430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/41/42647?source=see_link\">",
"      see \"Fosinopril: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypertension: Children &ge;6 years and &gt;50 kg: Oral: Initial: 5-10 mg once daily (maximum: 40 mg/day)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F174412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F174413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None needed since hepatobiliary elimination compensates adequately diminished renal elimination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Moderately dialyzable (20% to 50%)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F174414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decrease dose and monitor effects",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F174380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sodium: 10 mg, 20 mg, 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F174364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F174383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension, either alone or in combination with other antihypertensive agents; treatment of heart failure (HF)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F174453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fosinopril may be confused with FLUoxetine, Fosamax&reg;, furosemide, lisinopril",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Monopril may be confused with Accupril&reg;, minoxidil, moexipril, Monoket&reg;, Monurol&reg;, ramipril",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F174443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Frequency ranges include data from hypertension and heart failure trials. Higher rates of adverse reactions have generally been noted in patients with CHF. However, the frequency of adverse effects associated with placebo is also increased in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Dizziness (1.6% to 11.9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension (1.4% to 1.9%), palpitation (1.4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (1% to 2%; up to 12% in CHF patients), headache (3.2%), fatigue (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia (2.6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (2.2%), nausea/vomiting (1.2% to 2.2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain (&lt;1% to 3.3%), noncardiac chest pain (&lt;1% to 2.2%), weakness (1.4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increased, renal function worsening (in patients with bilateral renal artery stenosis or hypovolemia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (2.2% to 9.7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Upper respiratory infection (2.2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;1% but &le; frequency in patients receiving placebo: Sexual dysfunction, fever, flu-like syndrome, dyspnea, rash, headache, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactoid reaction, angina, angioedema, arthralgia, bronchospasm, cerebral infarction, cerebrovascular accident, gout, hepatitis, hepatomegaly, myalgia, MI, pancreatitis, paresthesia, photosensitivity, pleuritic chest pain, pruritus, rash, renal insufficiency, shock, sudden death, syncope, TIA, tinnitus, urticaria, vertigo. In a small number of patients, a symptom complex of cough, bronchospasm, and eosinophilia has been observed with fosinopril.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Other events reported with ACE inhibitors: Acute renal failure, agranulocytosis, anemia, aplastic anemia, bullous pemphigus, cardiac arrest, eosinophilic pneumonitis, exfoliative dermatitis, gynecomastia, hemolytic anemia, hepatic failure, jaundice, neutropenia, pancytopenia, Stevens-Johnson syndrome, symptomatic hyponatremia, thrombocytopenia. In addition, a syndrome which may include fever, myalgia, arthralgia, interstitial nephritis, vasculitis, rash, eosinophilia and positive ANA, and elevated ESR has been reported for other ACE inhibitors.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F174386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fosinopril, any other ACE inhibitor, or any component of the formulation; angioedema related to previous treatment with an ACE inhibitor; concomitant use with aliskiren in patients with diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F174368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: At any time during treatment (especially following first dose), angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans and patients with idiopathic or hereditary angioedema may be at an increased risk. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Use in patients with previous angioedema associated with ACE inhibitor therapy is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: May occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenia/agranulocytosis: Another ACE Inhibitor, captopril, has been associated with rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Collagen vascular disease: Use with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in pre-existing renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin receptor blockers (ARBs) and renin inhibitors: Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;6 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Based on human data, ACEIs can cause injury and death to the developing fetus when used in the second and third trimesters. ACEIs should be discontinued as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F174373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F174402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Potassium supplements and/or potassium-containing salts may cause or worsen hyperkalemia. Management: Consult prescriber before consuming a potassium-rich diet, potassium supplements, or salt substitutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Some herbal medications may worsen hypertension (eg, licorice); others may increase the antihypertensive effect of fosinopril (eg, shepherd's purse). Management: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice, and yohimbe. Avoid black cohosh, california poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F174376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (1st trimester); D (2nd and 3rd trimesters) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F174389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to adverse events observed in some animal studies, fosinopril is considered pregnancy category C during the first trimester. Based on human data, fosinopril is considered pregnancy category D if used during the second and third trimesters (per the manufacturer; however, one study suggests that fetal injury may occur at anytime during pregnancy). First trimester exposure to ACE inhibitors may cause major congenital malformations. An increased risk of cardiovascular and/or central nervous system malformations was observed in one study; however, an increased risk of teratogenic events was not observed in other studies. Second and third trimester use of an ACE inhibitor is associated with oligohydramnios. Oligohydramnios due to decreased fetal renal function may lead to fetal limb contractures, craniofacial deformation, and hypoplastic lung development. The use of ACE inhibitors during the second and third trimesters is also associated with anuria, hypotension, renal failure (reversible or irreversible), skull hypoplasia, and death in the fetus/neonate. Chronic maternal hypertension itself is also associated with adverse events in the fetus/infant. ACE inhibitors are not recommended during pregnancy to treat maternal hypertension or heart failure. Those who are planning a pregnancy should be considered for other medication options if an ACE inhibitor is currently prescribed or the ACE inhibitor should be discontinued as soon as possible once pregnancy is detected. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed to an ACE inhibitor",
"     <i>",
"      in utero",
"     </i>",
"     , especially during the second and third trimester, should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      [U.S. Boxed Warning]: Based on human data, ACE inhibitors can cause injury and death to the developing fetus when used in the second and third trimesters. ACE inhibitors should be discontinued as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F174417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6198495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fosinoprilat is excreted in breast milk. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F174390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should not take a potassium salt supplement without the advice of healthcare provider.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F174388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Fosinopril Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (90): $107.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (90): $107.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (90): $107.08",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F174378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; serum creatinine and potassium; if patient has collagen vascular disease and/or renal impairment, periodically monitor CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F174391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acenor-M (ID);",
"     </li>",
"     <li>",
"      BPNorm (PH);",
"     </li>",
"     <li>",
"      Dynacil (DE);",
"     </li>",
"     <li>",
"      Fonosil (TW);",
"     </li>",
"     <li>",
"      Forsine (TW);",
"     </li>",
"     <li>",
"      Fosavis (SE);",
"     </li>",
"     <li>",
"      Fosinil (BE, ES, LU);",
"     </li>",
"     <li>",
"      Fosinorm (DE);",
"     </li>",
"     <li>",
"      Fosipres (IT);",
"     </li>",
"     <li>",
"      Fosipril (AU);",
"     </li>",
"     <li>",
"      Fositen (CH, PT);",
"     </li>",
"     <li>",
"      Fositens (AE, AT, BH, CY, EG, ES, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Fovas (IN);",
"     </li>",
"     <li>",
"      Fozitec (FR);",
"     </li>",
"     <li>",
"      Hiperlex (ES);",
"     </li>",
"     <li>",
"      Monace (AU);",
"     </li>",
"     <li>",
"      Monopril (AU, BB, BG, BM, BR, BS, BZ, CL, CN, CO, CZ, DK, EE, GR, GY, HK, HN, HU, JM, KP, MX, MY, NO, PE, PK, PL, RU, SE, SR, TH, TR, TT, TW, VE, ZA);",
"     </li>",
"     <li>",
"      Newace (NL);",
"     </li>",
"     <li>",
"      Sapril (PH);",
"     </li>",
"     <li>",
"      Staril (GB);",
"     </li>",
"     <li>",
"      Tenso Stop (ES);",
"     </li>",
"     <li>",
"      Tensocardil (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F174367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion; a CNS mechanism may also be involved in hypotensive effect as angiotensin II increases adrenergic outflow from CNS; vasoactive kallikreins may be decreased in conversion to active hormones by ACE inhibitors, thus reducing blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F174385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 36%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Prodrug, hydrolyzed to its active metabolite fosinoprilat by intestinal wall and hepatic esterases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 36%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination, serum (fosinoprilat): 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces (as fosinoprilat and other metabolites in roughly equal proportions, 45% to 50%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, &ldquo;Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(23):2981-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/12479763/pubmed\" id=\"12479763\" target=\"_blank\">",
"        12479763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):e1-e157.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/17692738/pubmed\" id=\"17692738\" target=\"_blank\">",
"        17692738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chase MP, Fiarman GS, Scholz FJ, et al, &ldquo;Angioedema of the Small Bowel Due to an Angiotensin-Converting Enzyme Inhibitor,&rdquo;",
"      <i>",
"       J Clin Gastroenterol",
"      </i>",
"      , 2000, 31(3):254-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/11034011/pubmed\" id=\"11034011\" target=\"_blank\">",
"        11034011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Hernandez-Diaz S, Arbogast PG, et al, &ldquo;Major Congenital Malformations After First-Trimester Exposure to ACE Inhibitors,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(23):2443-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/16760444/pubmed\" id=\"16760444\" target=\"_blank\">",
"        16760444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fox KM and EURopean Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators, &ldquo;Efficacy of Perindopril in Reduction of Cardiovascular Events Among Patients With Stable Coronary Artery Disease: Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial (The EUROPA Study),&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):782-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/13678872/pubmed\" id=\"13678872\" target=\"_blank\">",
"        13678872",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2002, 39(2 Suppl 2):1-246. Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/11904577/pubmed\" id=\"11904577\" target=\"_blank\">",
"        11904577",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mastrobattista JM, &ldquo;Angiotensin Converting Enzyme Inhibitors in Pregnancy,&rdquo;",
"      <i>",
"       Semin Perinatol",
"      </i>",
"      , 1997, 21(2):124-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/9201818/pubmed\" id=\"9201818\" target=\"_blank\">",
"        9201818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114 (2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Packer M, Poole-Wilson PA, Armstrong PW, et al, &ldquo;Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 100(23):2312-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/10587334/pubmed\" id=\"10587334\" target=\"_blank\">",
"        10587334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, Greaves SC, Arnold JM, et al, &ldquo;Early Versus Delayed Angiotensin-Converting Enzyme Inhibition Therapy in Acute Myocardial Infarction. The Healing and Early Afterload Reducing Therapy Trial,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1997, 95(12):2643-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/9193433/pubmed\" id=\"9193433\" target=\"_blank\">",
"        9193433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, &ldquo;Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349(20):1893-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/14610160/pubmed\" id=\"14610160\" target=\"_blank\">",
"        14610160",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quan A , &ldquo;Fetopathy Associated With Exposure to Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists,&rdquo;",
"      <i>",
"       Early Hum Dev",
"      </i>",
"      , 2006, 82(1):23-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/16427219/pubmed\" id=\"16427219\" target=\"_blank\">",
"        16427219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smoger SH and Sayed MA, &ldquo;Simultaneous Mucosal and Small Bowel Angioedema Due to Captopril,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1998, 91(11):1060-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/9824192/pubmed\" id=\"9824192\" target=\"_blank\">",
"        9824192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yusuf S, Sleight P, Pogue J, et al, &ldquo;Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. The Heart Outcomes Prevention Evaluation Study Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 342(3):145-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/30/16872/abstract-text/10639539/pubmed\" id=\"10639539\" target=\"_blank\">",
"        10639539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8479 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.81.197.98-ABAC7C5777-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_30_16872=[""].join("\n");
var outline_f16_30_16872=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708812\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174408\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174445\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174411\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174430\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174412\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174413\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174414\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174380\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174364\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174383\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174453\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174443\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174386\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174368\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299366\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174373\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174402\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174376\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174389\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174417\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6198495\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174390\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174388\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174378\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174391\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174367\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174385\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8479\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8479|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/39/15989?source=related_link\">",
"      Fosinopril: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/41/42647?source=related_link\">",
"      Fosinopril: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_30_16873="Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections";
var content_f16_30_16873=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/30/16873/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/30/16873/contributors\">",
"     Anthony W Chow, MD, FRCPC, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/30/16873/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/30/16873/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/30/16873/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/30/16873/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/30/16873/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Odontogenic infections, consisting primarily of dental caries and periodontal disease (gingivitis and periodontitis), are common and have local (eg, tooth loss) and, in some cases, systemic implications. In the United States, it is estimated that 25 percent of adults over the age of 60 have lost all their teeth (edentulism), approximately one-half from periodontal disease and one-half from dental caries [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to producing pain and discomfort, odontogenic infections can extend beyond natural barriers and result in potentially life-threatening complications, such as infections of the deep fascial spaces of the head and neck. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link\">",
"     \"Deep neck space infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Periodontal infection can also be associated with a number of systemic disorders. These include fever of unknown origin, bacteremic seeding of heart valves and prosthetic devices, preterm birth of low birth weight children, and an increased risk for coronary heart disease and cerebrovascular events. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Association with cardiovascular risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A thorough understanding of the anatomic considerations and salient clinical features is essential for early recognition and effective treatment of these infections and their complications. The epidemiology, pathogenesis, and clinical manifestations of odontogenic infections will be reviewed here. The gingivitis and periodontitis syndromes that can occur and the complications, diagnosis, and treatment of these infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18777?source=see_link\">",
"     \"Gingivitis and periodontitis in adults: Classification and dental treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/53/20313?source=see_link\">",
"     \"Complications, diagnosis, and treatment of odontogenic infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both dental caries and periodontal disease are prevalent in the United States and other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/1\">",
"     1",
"    </a>",
"    ]. In a report from the National Health and Nutrition Examination Survey (NHANES) involving 8366 noninstitutionalized adults in the United States from 1988 to 1991, approximately 90 percent were dentate but only 30 percent still retained all of their natural teeth [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a series of subsequent studies from NHANES demonstrated a substantial reduction in the prevalence rates of both dental caries and periodontal disease since 1988 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. The magnitude of this effect was illustrated in a report that demonstrated the following differences when 1999 to 2002 results were compared with those from 1988 to 1994 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduction in the prevalence of caries in permanent teeth of up to 10 percent occurred among persons aged 6 to 19 years, and up to 6 percent among dentate adults 20 years of age or older.",
"     </li>",
"     <li>",
"      A 6 percent reduction in total tooth loss (edentulism) among persons aged 60 years or older.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This global trend toward better dental health has been attributed to a variety of factors including fluoridation of drinking water, use of dentifrices, improved diet with sucrose substitutes, and emphasis on oral health.",
"   </p>",
"   <p>",
"    Despite these favorable trends, the overall burden of dental caries and periodontal disease remains high, particularly since both diseases are diagnosable, treatable, and potentially preventable [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In a report of NHANES data from 2009 and 2010, 64.7 million adults older than age 30 had periodontitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/7\">",
"     7",
"    </a>",
"    ]. Worldwide, 15 to 20 percent of adults between the ages of 35 and 44 years have severe periodontal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main cause of tooth loss varies with age. Dental caries is most important before the age of 35 and periodontal disease after the age of 35. Both tooth decay and periodontal disease are important contributors to tooth loss after age 60. However, loss of teeth is no longer considered an inevitable and irreversible part of aging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humans have two sets of teeth: deciduous (milk or baby) teeth and permanent teeth. The 20 deciduous teeth erupt at approximately six months to two years of age and are shed between the ages of 6 and 12. These are gradually replaced by 32 permanent teeth, consisting in each half jaw of two incisors, one canine, two premolars, and, in adults, three molars.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tooth structure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each tooth has a visible crown that projects above the gingiva (gum), with one or more roots extending into the alveolar bone of the maxilla or mandible (",
"    <a class=\"graphic graphic_figure graphicRef68403 \" href=\"UTD.htm?5/47/5880\">",
"     figure 1",
"    </a>",
"    ). The crown and root meet at the neck of the tooth.",
"   </p>",
"   <p>",
"    The tooth forms a peg and socket joint with the alveolar bone and is held in place by the periodontal membrane, which allows slight movement of the tooth. The hard tissues of the tooth are dentin, enamel, and cementum; the soft tissues are the pulp, the periodontal membrane, and the gingiva (",
"    <a class=\"graphic graphic_figure graphicRef68403 \" href=\"UTD.htm?5/47/5880\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The pulp filling the core of the tooth is composed of fibroblasts and connective tissue, and is supplied by blood vessels and nerves entering the pulp cavity through the apical foramen. At the periphery of the pulp is a layer of odontoblasts. Odontoblastic processes extend through the dentin in small canals called dentinal tubules. The odontoblasts with their processes lay down dentin, which forms the bulk of the tooth. Dentin is similar to bone but is harder because of a greater calcium content.",
"   </p>",
"   <p>",
"    The crown of the tooth is covered with enamel (",
"    <a class=\"graphic graphic_figure graphicRef68403 \" href=\"UTD.htm?5/47/5880\">",
"     figure 1",
"    </a>",
"    ), which is 99 percent inorganic and the hardest material in the body. The ultrastructure of enamel reveals units called enamel rods or prisms, which are embedded in a matrix. Both the rods and the interprismatic matrix are composed of apatite crystals.",
"   </p>",
"   <p>",
"    Enamel is laid down by ameloblasts, which form a membrane called the enamel cuticle on the surface of the unerupted tooth. With eruption of the tooth, the cuticle is worn off and lost.",
"   </p>",
"   <p>",
"    Similar to enamel coverage of dentin in the crown, cementum covers dentin in the root of the tooth from the neck to the apex. Cementum is structurally similar to bone, with cementocytes lying in lacunae and interconnected by canaliculi. Thick collagen bundles, known as Sharpey's fibers, run from the alveolar bone through the periodontal tissue into the cementum, and serve to anchor the tooth to the surrounding connective tissue.",
"   </p>",
"   <p>",
"    Finally, the gingiva surrounds each tooth like a collar and extends down over the crest of the alveolar bone to connect to the tooth just above the neck. The space formed between the tooth and the gingiva is called the gingival crevice or recess.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Spread of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Odontogenic infections originate from plaque composed of bacteria that colonize the surfaces of the tooth. The type of infection varies with the site of the plaques:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plaques located on tooth surfaces above the gingival margin (supragingival plaque) lead to dental caries that may invade the pulp (pulpitis or endodontic infection), and eventually perforate the alveolar bone (periapical abscess).",
"     </li>",
"     <li>",
"      Plaques located on tooth surfaces beneath the gingival margin (subgingival plaque) lead to periodontal infections (eg, gingivitis, periodontitis, and periodontal abscess) that may eventually penetrate the fascial spaces of the face and mouth (orofacial space infections).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Soft tissue infections of odontogenic origin tend to spread along planes of least resistance from the supporting structures of the affected tooth to various potential spaces in the vicinity (",
"    <a class=\"graphic graphic_figure graphicRef77988 \" href=\"UTD.htm?6/14/6368\">",
"     figure 2",
"    </a>",
"    ). Accumulated pus must perforate bone, generally at the site where it is thinnest and weakest, before extending into the periapical areas or deeper fascial spaces. In the mandible, for example, the two points where the bone is weakest and where perforation tends to occur are on the lingual aspect in the region of the molar teeth, and anteriorly on the buccal aspect [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In the maxilla, the bone is weakest on the buccal aspect throughout, and is relatively thicker on the palatal aspect.",
"   </p>",
"   <p>",
"    The local anatomic barriers of bone, muscle, and fascia predetermine the routes of spread, extent, and clinical manifestations of many orofacial infections of odontogenic origin:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If pus perforates through either the maxillary or mandibular buccal plate inside the attachment of the buccinator muscle, infection will be intraoral; if the perforation is outside this muscle attachment, infection will be extraoral (",
"      <a class=\"graphic graphic_figure graphicRef77988 \" href=\"UTD.htm?6/14/6368\">",
"       figure 2",
"      </a>",
"      ). Thus, infection of the upper and lower molars, lower incisors, and lower canine teeth is often accompanied by extraoral manifestations.",
"     </li>",
"     <li>",
"      When a mandibular infection perforates lingually, it presents in the sublingual space if the apices of the involved teeth lie above the attachment of the mylohyoid muscle (eg, mandibular incisor, canines, premolars, and first molars), and in the submandibular space if below the attachment of the muscle (eg, the second and third molars) (",
"      <a class=\"graphic graphic_figure graphicRef77988 \" href=\"UTD.htm?6/14/6368\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are a number of clinically important \"fascial spaces\" around the face and oral cavity that are often involved in odontogenic infections (",
"    <a class=\"graphic graphic_figure graphicRef80359 \" href=\"UTD.htm?0/23/372\">",
"     figure 3",
"    </a>",
"    ). These are potential spaces between layers of fascia that communicate with one another to varying degrees. A thorough understanding of the \"anatomic routes\" of infection provides valuable information about the nature and extent of infection and also suggests the optimal surgical approach for drainage. Infections involving the deep fascial spaces of the neck are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link\">",
"     \"Deep neck space infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND PREDISPOSING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned in the preceding section, plaque formation plays a central role in both dental caries and periodontal infection and the type of infection varies with the site of the plaque.",
"   </p>",
"   <p>",
"    Both host and microbial factors influence plaque formation and its ability to cause dental caries or periodontal disease. Oral hygiene, diet, and genetic predisposition are determinants of risk [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dental caries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dental caries refers to the localized destruction of dental hard tissues by plaque bacteria that are acidogenic (acid-producing) and aciduric (able to grow at low pH), particularly Streptococcus mutans and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    spp, which also colonize the tooth surface [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Pathogenesis of caries'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Teeth have at least three intrinsic mechanisms that protect against carious decay:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A constant flow of saliva, which is at a neutral pH, bathes the tooth, buffers and washes away bacterial acids, and supplies calcium and phosphate to remineralize and repair damaged tooth surfaces. In addition, saliva and its various constituents, such as lactoferrin, lysozyme, lactoperoxidase, beta-lysin, and immunoglobulins, possess important antimicrobial activity against plaque-associated bacteria.",
"     </li>",
"     <li>",
"      The cleansing action of the tongue and buccal membranes, which remove food particles from the proximity of the tooth.",
"     </li>",
"     <li>",
"      The acquisition by the tooth of an acellular structureless bacteria-free coating known as the acquired pellicle, which is of salivary origin and acts as a surface barrier to most dietary and bacterial acids [",
"      <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The oral cavity also has an innate immune response that is characterized by secretion of various antimicrobial peptides (defensins) by oral epithelial tissues in response to bacterial stimuli or inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Commensal and pathogenic bacteria utilize different pathways in defensin induction, and epithelial cells from different body sites appear to have common signaling mechanisms to distinguish commensal from pathogenic bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A final protective modality is tooth brushing and flossing to physically remove food particles and bacterial plaques adherent to the tooth surface. With poor dental hygiene, the acquired pellicle becomes colonized with bacteria and is replaced by supragingival and subgingival bacterial plaques that ultimately progress to dental caries.",
"   </p>",
"   <p>",
"    Older individuals form dental plaques more rapidly, although patients of all ages are susceptible to the development of plaque if daily oral care is withheld [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/14\">",
"     14",
"    </a>",
"    ]. Gingival recession, which is both more common and more severe with advancing age [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], increases the susceptibility to root caries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Periodontal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodontal disease is mainly caused by microorganisms within the subgingival dental plaque, which penetrate the gingival epithelium, elicit an inflammatory host response, and ultimately result in destruction of the periodontium (",
"    <a class=\"graphic graphic_figure graphicRef68403 \" href=\"UTD.htm?5/47/5880\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/6,17\">",
"     6,17",
"    </a>",
"    ]. This tissue destruction results in apical migration of gingival tissues (gingival recession), loss of periodontal attachment, and an increase in the depth of the gingival crevice (periodontal pockets). (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Pathogenesis of periodontal disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Predisposing factors for periodontal disease include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inadequate oral hygiene and increasing age, which are the two major risk factors",
"     </li>",
"     <li>",
"      Hormonal effects, with exacerbation of disease activity during puberty, menstruation, and pregnancy",
"     </li>",
"     <li>",
"      Certain underlying diseases, such as diabetes mellitus, various genetic disorders that impair neutrophil function, and rheumatoid arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/18-21\">",
"       18-21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bone loss is a serious complication of periodontal disease. The mechanism by which this might occur was evaluated in a study in which peripheral blood lymphocytes from patients with periodontitis were transplanted into immunodeficient mice [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/22\">",
"     22",
"    </a>",
"    ]. Actinobacillus actinomycetemcomitans stimulated the human CD4+ cells to express osteoprotegerin ligand, which is an osteoclast activator.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Microbial specificity in odontogenic infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the healthy oral cavity, Streptococcus, Peptostreptococcus, Veillonella, and diphtheroids account for more than 80 percent of the total cultivable flora (",
"    <a class=\"graphic graphic_table graphicRef81076 \" href=\"UTD.htm?26/38/27244\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/9\">",
"     9",
"    </a>",
"    ]. Quantitative studies indicate that obligate anaerobes are present in numbers as much as eight times those of facultative bacteria in certain locations.",
"   </p>",
"   <p>",
"    Many clinically significant oral anaerobic gram-negative bacilli previously included under the \"oral Bacteroides\" group, are now reclassified as Porphyromonas or Prevotella species [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/23\">",
"     23",
"    </a>",
"    ]. Facultative gram-negative bacilli are uncommon in the healthy host, but may be more prominent in seriously ill and hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The oral cavity cannot be regarded as a single uniform environment. Although representative species of microorganisms can be isolated from most areas of the mouth, specific organisms tend to colonize certain sites. As an example, Streptococcus salivarius and Veillonella spp have a predilection for the tongue and buccal mucosa and predominate before the eruption of teeth [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/9\">",
"     9",
"    </a>",
"    ]. In contrast, Streptococcus sanguinis (formerly S. sanguis), Streptococcus mutans, and Actinomyces viscosus preferentially colonize the tooth surface. Fusobacterium, pigmented Prevotella, and anaerobic spirochetes appear to be concentrated in the gingival crevice.",
"   </p>",
"   <p>",
"    Bacterial adherence and interaggregation, local environmental conditions, such as oxygen tension and pH, and other host factors seem to govern these unique colonization patterns and influence the composition of the oral flora.",
"   </p>",
"   <p>",
"    There is growing awareness of the infectious nature of dental caries, and that only certain microorganisms residing within dental plaques are cariogenic (ie, the specific plaque hypothesis of dental caries and periodontal disease) (",
"    <a class=\"graphic graphic_figure graphicRef80644 \" href=\"UTD.htm?2/3/2111\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. This hypothesis states that there are non-diseased plaques, which are associated with good dental health, and that environmental influences cause rearrangement of this \"normal\" flora, which can lead to either cariogenic or periodontopathic plaques [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pathogenesis of caries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dental caries are caused by microorganisms within the supragingival plaque, which include gram-positive facultative and microaerophilic cocci and rods. The mutans group of streptococci, particularly S. mutans and S. sobrinus, are the primary organisms associated with dental caries [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The ingestion of carbohydrates, especially monosaccharides and disaccharides is also important [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of decayed fissures have identified high levels of these mutans streptococci, as have studies comparing the microflora of carious and non-carious teeth [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/27\">",
"     27",
"    </a>",
"    ]. These streptococci are transmissible between humans, and infants are often infected by salivary contact with their mothers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    S. mutans readily colonize the tooth surface shortly after eruption. However, they do not become cariogenic until exposed to dietary sucrose, which can be rapidly sequestered and utilized by plaque-associated organisms, including S. mutans, some lactobacilli, and other acidogenic and aciduric organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following mechanisms contribute to this process [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plaque bacteria that ferment dietary sucrose produce acids that lower the pH on the tooth surface, promoting demineralization and eventually, tooth decay.",
"     </li>",
"     <li>",
"      Plaque bacteria, such as S. mutans can also utilize sucrose to produce extracellular polysaccharides, known as glucans, which are adhesive polymers that enable mutans streptococci to avidly stick to the tooth surface, thereby causing decay in the underlying structures [",
"      <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, both acidogenicity (ability to produce acid) and aciduricity (ability to grow at low pH) are important attributes for S. mutans and lactobacilli to survive and flourish within a cariogenic plaque and cause tooth decay.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pathogenesis of periodontal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with dental caries, a unique and specific bacterial composition of the subgingival plaque has been identified in gingivitis and periodontitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/28,31\">",
"     28,31",
"    </a>",
"    ]. In the healthy periodontium, the microflora are sparse and consist mainly of gram-positive organisms, such as Streptococcus sanguinis and Actinomyces spp. In the presence of gingivitis, the predominant subgingival flora shift to a greater proportion of anaerobic gram-negative bacilli, with Prevotella intermedia as the predominant isolate [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In well-established periodontitis, the flora further increase in complexity with a preponderance of anaerobic gram-negative bacilli and motile organisms. Aggregatibacter (Actinobacillus) actinomycetemcomitans (a HACEK infection), Porphyromonas gingivalis, Prevotella intermedia, Treponema denticola, and Tannerella forsythensis (formerly, Bacteroides forsythus) are the predominant isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In juvenile periodontitis, a clinical variant seen primarily in adolescents, the subgingival plaque mainly consists of saccharolytic organisms, with A. actinomycetemcomitans and Capnocytophaga spp as the most common identifiable isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/34\">",
"     34",
"    </a>",
"    ]. P. gingivalis is rarely found in this condition. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Periodontitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Animal and human studies have shown that periodontal disease is caused by tissue destruction due to inflammation induced by a predominantly anaerobic periodontopathic subgingival plaque flora [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Specific virulence factors by selective periodontopathic bacteria, such as lipopolysaccharide and proteolytic enzymes, play a role. However, host factors, such as an exaggerated inflammatory response and genetic predisposition, as well as environmental factors, such as smoking and malnutrition, may be even more important [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to its role in dental caries, dietary carbohydrate intake does not appear to have a significant role in the pathogenesis of periodontal disease.",
"   </p>",
"   <p>",
"    Suppurative odontogenic infections, such as periapical abscess or fascial space infections, occur when local or systemic host defenses breakdown, due to disruption of mucosal barriers or immunocompromise from underlying disease. Polymicrobial flora are usually present, with Fusobacterium nucleatum, pigmented Prevotella, Peptostreptococcus, Actinomyces, and Streptococcus spp as the most predominant isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. With the exception of selected patients with serious underlying illnesses, facultative gram-negative bacilli and Staphylococcus aureus are uncommonly isolated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Odontogenic infections originate from the dentoalveolar structures, the periodontium, or the pericoronal tissues (",
"    <a class=\"graphic graphic_figure graphicRef65240 \" href=\"UTD.htm?35/4/35907\">",
"     figure 5",
"    </a>",
"    ). In addition to local symptoms, these infections can also be associated with a number of systemic disorders. These include fever of unknown origin, bacteremic seeding of heart valves and prosthetic devices, preterm birth of low birth weight children, and an increased risk for coronary heart disease and cerebrovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Dentoalveolar infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dentoalveolar infections include dental caries, pulpitis, and periapical abscess.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Dental caries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caries occur at either the coronal or root surfaces of the affected tooth (",
"    <a class=\"graphic graphic_figure graphicRef68403 \" href=\"UTD.htm?5/47/5880\">",
"     figure 1",
"    </a>",
"    ). The prevalence of coronal caries among dentate persons in the United States increases rapidly with age up to the mid-forties and remains stable thereafter; in contrast, the prevalence of root caries continues to increase dramatically with advancing age [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/1,42\">",
"     1,42",
"    </a>",
"    ]. Coronal caries are more likely to present as recurrent lesions around existing restorations; they are more difficult to detect clinically than new carious lesions.",
"   </p>",
"   <p>",
"    The earliest findings are the presence of pits and fissures on the affected tooth surface, which gradually becomes stained due to demineralization of enamel and dentin. Further destruction eventually leads to collapse of the overlying enamel. Since there are no cells or vascular elements in enamel or dentin except for the secondary odontoblasts lying on the pulpal surface, the diseased area is incapable of healing and replacement.",
"   </p>",
"   <p>",
"    The typical clinical presentation of a new carious lesion is a soft to rubbery textured and discolored defect on the tooth surface. Rapidly progressive caries tend to be soft and can be painful due to involvement of the pulp.",
"   </p>",
"   <p>",
"    Most coronal caries develop slowly, since the infection must spread through highly calcified enamel and dentin. As a result, the lesions are more likely to be longstanding, hard, and asymptomatic. The carious process progresses silently until the infection has invaded deeply enough into the pulp to cause pulpal reaction, and eventually the crown is destroyed.",
"   </p>",
"   <p>",
"    Root caries occur on the tooth surface where gingival recession has occurred, and are characterized by discrete, well-defined, soft, and discolored defects on the root surface or at the junction of the crown and the root. Root caries can be more difficult to diagnose than coronal caries, since they tend to occur in the interproximal tooth surfaces, which are relatively inaccessible to brushing and are particularly prone to decay from retained food debris.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Pulpitis and periapical abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection of the pulp (pulpitis) can occur in one of three ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Through a defect in the enamel and dentin that results from extension of a carious lesion, traumatic fracture, or a dental procedure",
"     </li>",
"     <li>",
"      Through the apical foramen or lateral canals (eg, from a periodontal pocket or an adjacent tooth with a periapical abscess)",
"     </li>",
"     <li>",
"      Through hematogenous seeding of the pulp that has been irritated mechanically.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once infected, the acute inflammatory reaction causes a rapid build-up of pressure inside this rigid and unyielding space, compressing the blood vessels that enter the pulp cavity through the apical foramen, and causing ischemia and necrosis of the pulp tissue (",
"    <a class=\"graphic graphic_figure graphicRef68403 \" href=\"UTD.htm?5/47/5880\">",
"     figure 1",
"    </a>",
"    ). Pus may egress out of a cavity in the crown if one exists; it may extrude apically into the surrounding periodontal tissue, resulting in acute periapical periodontitis; or it may erode out of the apical foramen, resulting in periapical or alveolar abscess. The accumulation of pus causes loss of bone and periodontal tissue, and may extend to involve other teeth.",
"   </p>",
"   <p>",
"    The early and dominant symptom of acute pulpitis is a severe toothache that can be elicited by thermal changes, especially cold drinks. The involved tooth also may be sensitive to palpation and percussion. As the disease progresses, the pain becomes severe and continuous, with increased intensity in the recumbent position.",
"   </p>",
"   <p>",
"    In a more indolent form of the condition, called chronic pulpitis, the inflammation is low grade with partial drainage of the infected material. Symptoms are characterized by a mild and dull intermittent pain that is not affected by thermal changes.",
"   </p>",
"   <p>",
"    A more serious complication, lateral extension of the abscesses into planes of least resistance, results in deep fascial space involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link\">",
"     \"Deep neck space infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Periodontal infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodontal disease includes gingivitis and periodontitis. The main complication of periodontal disease is tooth loss, although local and systemic spread of infection can occur, leading to periodontal abscess and possibly orofacial space infections. The different syndromes are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18777?source=see_link\">",
"     \"Gingivitis and periodontitis in adults: Classification and dental treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Gingivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common periodontal disease in childhood, gingivitis, has a peak incidence in adolescence. The manifestations, which can range from mild to severe, include swelling, bluish purple discoloration of the gingiva, and a tendency to bleed after eating or brushing. There is usually no pain, but a mild fetor oris (halitosis) may be noticed.",
"   </p>",
"   <p>",
"    The inciting dental plaque may be difficult to observe until it has reached a certain thickness and becomes discolored or is calcified (calculus or tartar). Calculus is prevalent among all age groups, ranging from 74 to over 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/43\">",
"     43",
"    </a>",
"    ]. The frequency of subgingival calculus, but not the percentage of involved sites, increases directly with age, probably related to the preponderance of gingival recession and root caries in older individuals.",
"   </p>",
"   <p>",
"    Acute necrotizing ulcerative gingivitis (ANUG), also known as Vincent's angina or trench mouth, is relatively rare in the post-antibiotic era. The patient typically experiences a sudden onset of pain in the gingiva, and the tissue appears eroded with superficial grayish pseudomembranes. Other manifestations include halitosis, altered taste sensation, fever, malaise, and lymphadenopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Periodontitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic adult periodontitis, which is characterized by gingival inflammation with accompanying loss of supportive connective tissues including alveolar bone, results in loss of attachment of the periodontal ligament to the cementum. The prevalence of severe periodontal destruction (defined as 5 mm of loss of attachment or more) rises sharply with age, from 8 percent among adults 30 to 39 years of age to 35 percent among persons 60 to 69 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/15\">",
"     15",
"    </a>",
"    ]. However, the extent of severe involvement, even in elderly adults, is not high, with fewer than 5 percent of surveyed teeth affected in each individual. Similarly, the prevalence of deep periodontal pockets (defined as 5 mm or greater) is relatively low in all age groups (7 to 12 percent), with less than 2 percent of surveyed teeth affected among patients 60 years or older.",
"   </p>",
"   <p>",
"    The destructive process is slow, probably due to years of dental neglect and chronic gingivitis. Plaque and calculi are abundant both supragingivally and subgingivally, and frank pus may be present in the periodontal pockets. Rapidly progressive periodontitis is a variant in adults in whom the process of tissue loss is accelerated.",
"   </p>",
"   <p>",
"    In juvenile periodontitis or periodontosis in adolescents, there is rapid vertical bone loss often localized to the molars, although other teeth may be involved. Plaque is usually minimal, and calculi are not seen. The etiology of this rare condition is not known although neutrophil dysfunction has been reported in these otherwise healthy patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Periodontal abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodontal abscess may be focal or diffuse and presents as a red, fluctuant swelling of the gingiva, which is extremely tender to palpation. The abscesses always communicate with a periodontal pocket from which pus can be readily expressed after probing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pericoronitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericoronitis is an acute localized infection caused by food particles and microorganisms trapped under the gum flaps. The infection involves the wisdom teeth in adolescents and adults, and occurs during the eruption of the permanent teeth in children. The major symptoms include pain and limitation of movement on opening the jaw, discomfort on mastication and swallowing, and facial swelling.",
"   </p>",
"   <p>",
"    The pericoronal tissues are erythematous and swollen, and digital pressure can often express an exudate from under the infected flap. The masticator spaces are often involved, which can produce trismus. Localized painful lymphadenopathy may be noted, and the breath is usually foul.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Association with cardiovascular risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic poor oral health and tooth loss may be associated with modest increases in coronary and cerebrovascular disease; this effect appears to persist after adjustment for known cardiovascular disease risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/41,45-49\">",
"     41,45-49",
"    </a>",
"    ]. The magnitude of this effect was illustrated in a study of 1203 men followed for a median of 24 years in which radiographic bone loss was used as a marker of chronic periodontitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/46\">",
"     46",
"    </a>",
"    ]. Among men less than 60 years of age but not in older men, there was a significant dose-dependent increase in the risk of coronary heart disease (hazard ratio 2.12) comparing the highest versus the lowest category of radiographic bone loss.",
"   </p>",
"   <p>",
"    The mechanisms by which chronic periodontitis predisposes to coronary heart disease are not well understood, but an adverse effect of systemic inflammation on endothelial function may play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. In addition to local infection, other factors may contribute to systemic inflammation including intermittent bacteremia and release of bacterial endotoxins of oral origin into the bloodstream, an effect that can be induced by gentle chewing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of treating severe periodontitis on endothelial dysfunction was evaluated in a randomized trial in which 120 patients with severe periodontitis were assigned to either community-based periodontal care or intensive periodontal treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/53\">",
"     53",
"    </a>",
"    ]. The oral benefits of intensive therapy were associated with a significant improvement in endothelial function at six months. It is not known if intensive therapy would improve endothelial function in the long term or whether such interventions prevent the progression of cardiovascular disease or improve cardiovascular outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16873/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H213787719\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Odontogenic infections, consisting primarily of dental caries and periodontal disease (gingivitis and periodontitis), are common and have local (eg, tooth loss) and, in some cases, systemic implications. In addition to producing pain and discomfort, odontogenic infections can extend beyond natural barriers and result in potentially life-threatening complications, such as infections of the deep fascial spaces of the head and neck. The main cause of tooth loss varies with age. Dental caries is most important before the age of 35 and periodontal disease after the age of 35. Both tooth decay and periodontal disease are important contributors to tooth loss after age 60. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Each tooth has a visible crown that projects above the gingiva (gum), with one or more roots extending into the alveolar bone of the maxilla or mandible (",
"      <a class=\"graphic graphic_figure graphicRef68403 \" href=\"UTD.htm?5/47/5880\">",
"       figure 1",
"      </a>",
"      ). The crown and root meet at the neck of the tooth. The tooth forms a peg and socket joint with the alveolar bone and is held in place by the periodontal membrane, which allows slight movement of the tooth. The hard tissues of the tooth are dentin, enamel, and cementum; the soft tissues are the pulp, the periodontal membrane, and the gingiva (",
"      <a class=\"graphic graphic_figure graphicRef68403 \" href=\"UTD.htm?5/47/5880\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anatomic considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Odontogenic infections originate from plaque composed of bacteria that colonize the surfaces of the tooth. The type of infection varies with the site of the plaques:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Plaques located on tooth surfaces above the gingival margin (supragingival plaque) lead to dental caries that may invade the pulp (pulpitis or endodontic infection), and eventually perforate the alveolar bone (periapical abscess).",
"     </li>",
"     <li>",
"      Plaques located on tooth surfaces beneath the gingival margin (subgingival plaque) lead to periodontal infections (eg, gingivitis, periodontitis, and periodontal abscess) that may eventually penetrate the fascial spaces of the face and mouth (orofacial space infections). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Spread of infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Soft tissue infections of odontogenic origin tend to spread along planes of least resistance from the supporting structures of the affected tooth to various potential spaces in the vicinity (",
"      <a class=\"graphic graphic_figure graphicRef77988 \" href=\"UTD.htm?6/14/6368\">",
"       figure 2",
"      </a>",
"      ). The local anatomic barriers of bone, muscle, and fascia predetermine the routes of spread, extent, and clinical manifestations of many orofacial infections of odontogenic origin (",
"      <a class=\"graphic graphic_figure graphicRef80359 \" href=\"UTD.htm?0/23/372\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Spread of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dental caries are caused by microorganisms within the supragingival plaque, which include gram-positive facultative and microaerophilic cocci and rods. The mutans group of streptococci, particularly S. mutans and S. sobrinus, are the primary organisms associated with dental caries. The ingestion of carbohydrates, especially monosaccharides and disaccharides is also important. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pathogenesis of caries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the healthy periodontium, the microflora are sparse and consist mainly of gram-positive organisms, such as Streptococcus sanguinis and Actinomyces spp. In the presence of gingivitis, the predominant subgingival flora shift to a greater proportion of anaerobic gram-negative bacilli, with Prevotella intermedia as the predominant isolate. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pathogenesis of periodontal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Periodontal disease is caused by tissue destruction due to inflammation induced by a predominantly anaerobic periodontopathic subgingival plaque flora. In well-established periodontitis, the flora further increase in complexity with a preponderance of anaerobic gram-negative bacilli and motile organisms. Aggregatibacter (Actinobacillus) actinomycetemcomitans (a HACEK infection), Porphyromonas gingivalis, Prevotella intermedia, Treponema denticola, and Tannerella forsythensis (formerly, Bacteroides forsythus) are the predominant isolates. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pathogenesis of periodontal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dentoalveolar infections include dental caries, pulpitis, and periapical abscess. Caries occur at either the coronal or root surfaces of the affected tooth (",
"      <a class=\"graphic graphic_figure graphicRef68403 \" href=\"UTD.htm?5/47/5880\">",
"       figure 1",
"      </a>",
"      ). The typical clinical presentation of a new carious lesion is a soft to rubbery textured and discolored defect on the tooth surface. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Dentoalveolar infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The early and dominant symptom of acute pulpitis is a severe toothache that can be elicited by thermal changes, especially cold drinks. The involved tooth also may be sensitive to palpation and percussion. As the disease progresses, the pain becomes severe and continuous, with increased intensity in the recumbent position. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pulpitis and periapical abscess'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Periodontal disease includes gingivitis and periodontitis. The main complication of periodontal disease is tooth loss, although local and systemic spread of infection can occur, leading to periodontal abscess and possibly orofacial space infections. The manifestations of gingivitis, which can range from mild to severe, include swelling, bluish purple discoloration of the gingiva, and a tendency to bleed after eating or brushing. There is usually no pain, but a mild fetor oris (halitosis) may be noticed. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Periodontitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic adult periodontitis, which is characterized by gingival inflammation with accompanying loss of supportive connective tissues including alveolar bone, results in loss of attachment of the periodontal ligament to the cementum. The destructive process is slow, probably due to years of dental neglect and chronic gingivitis. Plaque and calculi are abundant both supragingivally and subgingivally, and frank pus may be present in the periodontal pockets. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Periodontitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic poor oral health and tooth loss may be associated with modest increases in coronary and cerebrovascular disease; this effect appears to persist after adjustment for known cardiovascular disease risk factors. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Association with cardiovascular risk'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/1\">",
"      Beltr&aacute;n-Aguilar ED, Barker LK, Canto MT, et al. Surveillance for dental caries, dental sealants, tooth retention, edentulism, and enamel fluorosis--United States, 1988-1994 and 1999-2002. MMWR Surveill Summ 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/2\">",
"      Marcus SE, Drury TF, Brown LJ, Zion GR. Tooth retention and tooth loss in the permanent dentition of adults: United States, 1988-1991. J Dent Res 1996; 75 Spec No:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/3\">",
"      Brown LJ, Wall TP, Lazar V. Trends in caries among adults 18 to 45 years old. J Am Dent Assoc 2002; 133:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/4\">",
"      Borrell LN, Burt BA, Taylor GW. Prevalence and trends in periodontitis in the USA: the [corrected] NHANES, 1988 to 2000. J Dent Res 2005; 84:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/5\">",
"      Selwitz RH, Ismail AI, Pitts NB. Dental caries. Lancet 2007; 369:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/6\">",
"      Loesche W. Dental caries and periodontitis: contrasting two infections that have medical implications. Infect Dis Clin North Am 2007; 21:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/7\">",
"      Eke PI, Dye BA, Wei L, et al. Prevalence of periodontitis in adults in the United States: 2009 and 2010. J Dent Res 2012; 91:914.",
"     </a>",
"    </li>",
"    <li>",
"     www.who.int/mediacentre/factsheets/fs318/en/ (Accessed on November 05, 2012).",
"    </li>",
"    <li>",
"     Chow AW. Infections of the oral cavity, neck and head. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2005. p.787.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/10\">",
"      Thadepalli H, Mandal AK. Anatomic basis of head and neck infections. Infect Dis Clin North Am 1988; 2:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/11\">",
"      Hull MW, Chow AW. Indigenous microflora and innate immunity of the head and neck. Infect Dis Clin North Am 2007; 21:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/12\">",
"      Dale BA, Fredericks LP. Antimicrobial peptides in the oral environment: expression and function in health and disease. Curr Issues Mol Biol 2005; 7:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/13\">",
"      Chung WO, Dale BA. Innate immune response of oral and foreskin keratinocytes: utilization of different signaling pathways by various bacterial species. Infect Immun 2004; 72:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/14\">",
"      Chow, AW. Odontogenic infections in the elderly. Infect Dis Clin Prac 1998; 6:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/15\">",
"      Albandar JM, Brunelle JA, Kingman A. Destructive periodontal disease in adults 30 years of age and older in the United States, 1988-1994. J Periodontol 1999; 70:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/16\">",
"      Brown LJ, L&ouml;e H. Prevalence, extent, severity and progression of periodontal disease. Periodontol 2000 1993; 2:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/17\">",
"      Kinane DF, Preshaw PM, Loos BG, Working Group 2 of Seventh European Workshop on Periodontology. Host-response: understanding the cellular and molecular mechanisms of host-microbial interactions--consensus of the Seventh European Workshop on Periodontology. J Clin Periodontol 2011; 38 Suppl 11:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/18\">",
"      Marotte H, Farge P, Gaudin P, et al. The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitope and severity of bone destruction. Ann Rheum Dis 2006; 65:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/19\">",
"      Ricci M, Garoia F, Tabarroni C, et al. Association between genetic risk score and periodontitis onset and progression: a pilot study. Arch Oral Biol 2011; 56:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/20\">",
"      Stashenko P, Van Dyke T, Tully P, et al. Inflammation and genetic risk indicators for early periodontitis in adults. J Periodontol 2011; 82:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/21\">",
"      Orbak R, Simsek S, Orbak Z, et al. The influence of type-1 diabetes mellitus on dentition and oral health in children and adolescents. Yonsei Med J 2008; 49:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/22\">",
"      Teng YT, Nguyen H, Gao X, et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 2000; 106:R59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/23\">",
"      Jousimies-Somer H, Summanen P. Recent taxonomic changes and terminology update of clinically significant anaerobic gram-negative bacteria (excluding spirochetes). Clin Infect Dis 2002; 35:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/24\">",
"      Valenti WM, Trudell RG, Bentley DW. Factors predisposing to oropharyngeal colonization with gram-negative bacilli in the aged. N Engl J Med 1978; 298:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/25\">",
"      Caufield PW, Griffen AL. Dental caries. An infectious and transmissible disease. Pediatr Clin North Am 2000; 47:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/26\">",
"      Mombelli A. Periodontitis as an infectious disease: specific features and their implications. Oral Dis 2003; 9 Suppl 1:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/27\">",
"      Hamada S, Slade HD. Biology, immunology, and cariogenicity of Streptococcus mutans. Microbiol Rev 1980; 44:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/28\">",
"      Kanasi E, Dewhirst FE, Chalmers NI, et al. Clonal analysis of the microbiota of severe early childhood caries. Caries Res 2010; 44:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/29\">",
"      Garc&iacute;a-Closas R, Garc&iacute;a-Closas M, Serra-Majem L. A cross-sectional study of dental caries, intake of confectionery and foods rich in starch and sugars, and salivary counts of Streptococcus mutans in children in Spain. Am J Clin Nutr 1997; 66:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/30\">",
"      Johnson MC, Bozzola JJ, Shechmeister IL, Shklair IL. Biochemical study of the relationship of extracellular glucan to adherence and cariogenicity in Streptococcus mutans and an extracellular polysaccharide mutant. J Bacteriol 1977; 129:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/31\">",
"      Socransky SS, Haffajee AD. Periodontal microbial ecology. Periodontol 2000 2005; 38:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/32\">",
"      Johnson TC, Reinhardt RA, Payne JB, et al. Experimental gingivitis in periodontitis-susceptible subjects. J Clin Periodontol 1997; 24:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/33\">",
"      L&oacute;pez R, Dahl&eacute;n G, Retamales C, Baelum V. Clustering of subgingival microbial species in adolescents with periodontitis. Eur J Oral Sci 2011; 119:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/34\">",
"      Slots J, Feik D, Rams TE. Actinobacillus actinomycetemcomitans and Bacteroides intermedius in human periodontitis: age relationship and mutual association. J Clin Periodontol 1990; 17:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/35\">",
"      Van Dyke TE, Sheilesh D. Risk factors for periodontitis. J Int Acad Periodontol 2005; 7:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/36\">",
"      Preshaw PM, Seymour RA, Heasman PA. Current concepts in periodontal pathogenesis. Dent Update 2004; 31:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/37\">",
"      Brook I. Microbiology and management of endodontic infections in children. J Clin Pediatr Dent 2003; 28:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/38\">",
"      Levi ME, Eusterman VD. Oral infections and antibiotic therapy. Otolaryngol Clin North Am 2011; 44:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/39\">",
"      Holmstrup P, Poulsen AH, Andersen L, et al. Oral infections and systemic diseases. Dent Clin North Am 2003; 47:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/40\">",
"      L&oacute;pez NJ, Da Silva I, Ipinza J, Guti&eacute;rrez J. Periodontal therapy reduces the rate of preterm low birth weight in women with pregnancy-associated gingivitis. J Periodontol 2005; 76:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/41\">",
"      Scannapieco FA, Bush RB, Paju S. Associations between periodontal disease and risk for atherosclerosis, cardiovascular disease, and stroke. A systematic review. Ann Periodontol 2003; 8:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/42\">",
"      Winn DM, Brunelle JA, Selwitz RH, et al. Coronal and root caries in the dentition of adults in the United States, 1988-1991. J Dent Res 1996; 75 Spec No:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/43\">",
"      Brown LJ, Brunelle JA, Kingman A. Periodontal status in the United States, 1988-1991: prevalence, extent, and demographic variation. J Dent Res 1996; 75 Spec No:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/44\">",
"      Haraszthy VI, Hariharan G, Tinoco EM, et al. Evidence for the role of highly leukotoxic Actinobacillus actinomycetemcomitans in the pathogenesis of localized juvenile and other forms of early-onset periodontitis. J Periodontol 2000; 71:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/45\">",
"      Hung HC, Joshipura KJ, Colditz G, et al. The association between tooth loss and coronary heart disease in men and women. J Public Health Dent 2004; 64:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/46\">",
"      Dietrich T, Jimenez M, Krall Kaye EA, et al. Age-dependent associations between chronic periodontitis/edentulism and risk of coronary heart disease. Circulation 2008; 117:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/47\">",
"      Humphrey LL, Fu R, Buckley DI, et al. Periodontal disease and coronary heart disease incidence: a systematic review and meta-analysis. J Gen Intern Med 2008; 23:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/48\">",
"      Friedewald VE, Kornman KS, Beck JD, et al. The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: periodontitis and atherosclerotic cardiovascular disease. Am J Cardiol 2009; 104:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/49\">",
"      Lockhart PB, Bolger AF, Papapanou PN, et al. Periodontal disease and atherosclerotic vascular disease: does the evidence support an independent association?: a scientific statement from the American Heart Association. Circulation 2012; 125:2520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/50\">",
"      Montebugnoli L, Servidio D, Miaton RA, et al. Periodontal health improves systemic inflammatory and haemostatic status in subjects with coronary heart disease. J Clin Periodontol 2005; 32:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/51\">",
"      De Nardin E. The role of inflammatory and immunological mediators in periodontitis and cardiovascular disease. Ann Periodontol 2001; 6:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/52\">",
"      Geerts SO, Nys M, De MP, et al. Systemic release of endotoxins induced by gentle mastication: association with periodontitis severity. J Periodontol 2002; 73:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16873/abstract/53\">",
"      Tonetti MS, D'Aiuto F, Nibali L, et al. Treatment of periodontitis and endothelial function. N Engl J Med 2007; 356:911.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3417 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F1B7A60FFB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_30_16873=[""].join("\n");
var outline_f16_30_16873=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H213787719\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tooth structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Spread of infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS AND PREDISPOSING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dental caries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Periodontal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Microbial specificity in odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pathogenesis of caries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pathogenesis of periodontal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Dentoalveolar infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Dental caries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Pulpitis and periapical abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Periodontal infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Gingivitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Periodontitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Periodontal abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pericoronitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Association with cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H213787719\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3417\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3417|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/47/5880\" title=\"figure 1\">",
"      Structure of tooth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/14/6368\" title=\"figure 2\">",
"      Spread odontogenic infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/23/372\" title=\"figure 3\">",
"      Fascial spaces mouth and face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/3/2111\" title=\"figure 4\">",
"      Microbes in odontogenic infx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/4/35907\" title=\"figure 5\">",
"      Types of odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3417|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/38/27244\" title=\"table 1\">",
"      Cultivable flora oral cavity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/53/20313?source=related_link\">",
"      Complications, diagnosis, and treatment of odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=related_link\">",
"      Deep neck space infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18777?source=related_link\">",
"      Gingivitis and periodontitis in adults: Classification and dental treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_30_16874="Differential diagnosis of abdominal pain in adults";
var content_f16_30_16874=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Differential diagnosis of abdominal pain in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/30/16874/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/30/16874/contributors\">",
"     Mary B Fishman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/30/16874/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/30/16874/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/30/16874/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/30/16874/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/30/16874/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/30/16874/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of abdominal pain requires an understanding of the possible mechanisms responsible for pain, a broad differential of common causes, and recognition of typical patterns and clinical presentations. All patients do not have classic presentations. Thus, unusual causes of abdominal pain must also be considered, especially in older adult and immunocompromised patients.",
"   </p>",
"   <p>",
"    An epidemiologic assessment of acute abdominal pain found that 10 diagnostic groups could be classified in outpatients complaining of abdominal pain on their first visit to primary care physicians: whole abdominal, epigastric, right subcostal, left subcostal, right flank, left flank, periumbilical, right-lower, mid-lower, and left-lower (",
"    <a class=\"graphic graphic_table graphicRef70233 \" href=\"UTD.htm?19/9/19613\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/1\">",
"     1",
"    </a>",
"    ]. The overall sensitivity of history taking and physical examination was poor. Specificity was highest in patients with epigastric pain caused by gastroduodenal diseases, right subcostal pain caused by hepatobiliary diseases, and mid-lower pain caused by gynecologic diseases.",
"   </p>",
"   <p>",
"    This topic review will provide an overview of the mechanisms and differential diagnosis in patients with abdominal pain. Detailed discussions of the specific causes of abdominal pain and initial management are presented separately. A detailed history and physical examination in adults with abdominal pain is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40323?source=see_link\">",
"     \"History and physical examination in adults with abdominal pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients with abdominal pain will have a functional disorder such as irritable bowel syndrome or functional dyspepsia. A diagnostic approach appropriate for most patients with abdominal pain and aimed at appropriately distinguishing functional disorders from more serious etiologies of abdominal pain is also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=see_link\">",
"     \"Diagnostic approach to abdominal pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEUROLOGIC BASIS OF ABDOMINAL PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain receptors in the abdomen respond to mechanical and chemical stimuli. Stretch is the principal mechanical stimulus involved in visceral nociception, although distention, contraction, traction, compression, and torsion are also perceived [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/2\">",
"     2",
"    </a>",
"    ]. Visceral receptors responsible for these sensations are located on serosal surfaces, within the mesentery, and within the walls of hollow viscera, in which they exist between the muscularis mucosa and submucosa.",
"   </p>",
"   <p>",
"    Mucosal receptors respond primarily to chemical stimuli, in contrast to other visceral nociceptors that respond to chemical or mechanical stimuli. A variety of chemical stimuli are capable of triggering these receptors including substance P, bradykinin, serotonin, histamine, and prostaglandins, which are released in response to inflammation or ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The events responsible for the perception of pain are not completely understood, but depend upon the type of stimulus and the interpretation of visceral nociceptive inputs in the central nervous system (CNS). Multiple types of stimuli may exist concurrently and influence the perception of pain. As an example, the gastric mucosa is insensitive to pressure or chemical stimuli. However, in the presence of pre-existing inflammation, these same stimuli can cause pain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Processing of visceral pain signals by the CNS is also important for their interpretation. The threshold for perceiving pain from visceral stimuli may vary among individuals and in certain diseases. As an example, distension of the sigmoid colon by a balloon is perceived as painful at lower distension thresholds in some patients with irritable bowel syndrome (IBS) compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, the perception of somatic pain in patients with IBS is similar to controls. Psychologic factors are also likely to be important in the perception of pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12697?source=see_link\">",
"     \"Pathophysiology of irritable bowel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Localization of pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type and density of visceral afferent nerves makes the localization of visceral pain imprecise. However, a few general rules are useful at the bedside:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most digestive tract pain is perceived in the midline because of bilaterally symmetric innervation [",
"      <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/2,7\">",
"       2,7",
"      </a>",
"      ]. Pain that is clearly lateralized most likely arises from the ipsilateral kidney, ureter, ovary, or somatically innervated structures, which have predominantly unilateral innervation. Exceptions to this rule include the gallbladder and ascending and descending colons which, although bilaterally innervated, have predominant innervation located on their ipsilateral sides.",
"     </li>",
"     <li>",
"      Visceral pain is perceived in the spinal segment at which the visceral afferent nerves enter the spinal cord [",
"      <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/8\">",
"       8",
"      </a>",
"      ]. As an example, afferent nerves mediating pain arising from the small intestine enter the spinal cord between T8 to L1. Thus, distension of the small intestine is usually perceived in the periumbilical region.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Referred pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain originating in the viscera may sometimes be perceived as originating from a site distant from the affected organ (",
"    <a class=\"graphic graphic_figure graphicRef61375 \" href=\"UTD.htm?23/54/24419\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. One explanation is that visceral afferent nerve fibers enter the spinal cord close to inputs from somatic receptors, and both types of inputs activate the same spinothalamic pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/12\">",
"     12",
"    </a>",
"    ]. Because the density of somatic inputs is higher than visceral inputs and because somatic inputs are more commonly stimulated, the brain tends to associate the stimulation with a somatic source.",
"   </p>",
"   <p>",
"    Referred pain is usually located in the cutaneous dermatomes sharing the same spinal cord level as the visceral inputs. As an example, nociceptive inputs from the gallbladder enter the spinal cord at T5 to T10. Thus, pain from an inflamed gallbladder may be perceived in the scapula (",
"    <a class=\"graphic graphic_figure graphicRef61375 \" href=\"UTD.htm?23/54/24419\">",
"     figure 1",
"    </a>",
"    ). Precise localization of the pain to the right upper quadrant in patients with acute cholecystitis usually occurs once the overlying parietal peritoneum (which is somatically innervated) becomes inflamed.",
"   </p>",
"   <p>",
"    The quality of referred pain is aching and perceived to be near the surface of the body. In addition to pain, two other correlates of referred pain can be detected: skin hyperalgesia and increased muscle tone of the abdominal wall (which accounts for the abdominal wall rigidity sometimes observed in patients with an acute abdomen).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Extra-abdominal causes of abdominal pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain perceived as originating in the abdomen may arise from extra-abdominal sites or from acute systemic illness (",
"    <a class=\"graphic graphic_table graphicRef60310 \" href=\"UTD.htm?12/4/12365\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/13\">",
"     13",
"    </a>",
"    ]. In patients with herpes zoster, for example, neuropathic pain may sometimes precede the development of skin lesions. An attack of herpes zoster involving the thoracic dermatomes can sometimes cause severe right upper quadrant pain, which can be confused with visceral causes such as acute cholecystitis (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21608?source=see_link\">",
"     \"Postherpetic neuralgia\"",
"    </a>",
"    ). Another example is lower thoracic or epigastric abdominal pain that may accompany acute myocardial infarction or ischemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=see_link\">",
"     \"Pathophysiology and clinical presentation of ischemic chest pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     UPPER ABDOMINAL PAIN SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The different pain syndromes typically, but not always, have characteristic locations (",
"    <a class=\"graphic graphic_table graphicRef70233 \" href=\"UTD.htm?19/9/19613\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Biliary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders involving the liver, biliary organs, pancreas, kidneys, stomach, intestines, diaphragms, and lung may cause right upper quadrant pain. The biliary tract syndromes are classified according to the source of pain and the pathogenesis of the disorder (eg, distention of a duct, inflammation, or infection).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cholelithiasis refers to the presence of gallstones within the gallbladder; it is often asymptomatic.",
"     </li>",
"     <li>",
"      Biliary colic is usually caused by the gallbladder contracting in response to a fatty meal and pressing a stone against the gallbladder outlet or cystic duct opening, leading to increased intragallbladder pressure and pain. The term biliary colic is a misnomer, since the pain is not typically colicky. It is entirely visceral in origin, without true gallbladder wall inflammation. Affected patients typically complain of deep and gnawing pain that is occasionally sharp and severe. The pain is localized in the right upper quadrant or epigastrium. As the gallbladder relaxes, the stones often fall back from the cystic duct. As a result, the attack reaches a crescendo over a number of hours and then resolves completely; it may recur multiple times. Biliary colic may be mistaken for irritable bowel syndrome, acute myocardial infarction, and peptic ulcer disease.",
"     </li>",
"     <li>",
"      Prolonged or recurrent cystic duct blockage can progress to total obstruction, causing acute cholecystitis. Patients with acute cholecystitis typically complain of abdominal pain, most often in the right upper quadrant or epigastrium with possible radiation to the right shoulder or back. The pain is characteristically steady and severe. Associated complaints may include nausea, vomiting, and anorexia. There is often a history of fatty food ingestion about one hour or more before the initial onset of pain. An episode of prolonged right upper quadrant pain (more than four to six hours), especially if associated with fever, should arouse suspicion for acute cholecystitis as opposed to an attack of simple biliary colic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute cholangitis occurs when a stone becomes impacted in the biliary or hepatic ducts, causing dilation of the obstructed duct and bacterial superinfection. It is characterized by fever, jaundice, and abdominal pain, although this classic triad occurs in only 50 to 75 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/14\">",
"       14",
"      </a>",
"      ]. The abdominal pain is typically vague and located in the right upper quadrant. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=see_link\">",
"       \"Acute cholangitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gallstone pancreatitis occurs when a gallstone becomes impacted within the ampulla of Vater, occluding drainage of the pancreatic duct. This is the most common cause of acute pancreatitis in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/15\">",
"       15",
"      </a>",
"      ]. The pain of gallstone pancreatitis is typical of acute pancreatitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Biliary dyskinesia, which is usually attributed to sphincter of Oddi dysfunction, can be a cause of biliary pain in the absence of gallstones or biliary inflammation. It can occur following cholecystectomy but is also diagnosed in patients whose gallbladder is intact. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=see_link\">",
"       \"Clinical manifestations and diagnosis of sphincter of Oddi dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acute pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all patients with acute pancreatitis have acute upper abdominal pain at the onset. The pain is steady and may be in the mid-epigastrium, right upper quadrant, diffuse, or, infrequently, confined to the left side. Biliary colic, which may herald or progress to acute pancreatitis, may occur postprandially, while acute pancreatitis related to alcohol frequently occurs one to three days after a binge or cessation of drinking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike biliary colic, which lasts a maximum of six to eight hours, the pain of pancreatitis lasts days. Its onset is rapid, but not as abrupt as that with a perforated viscus; in many cases, the pain of pancreatitis reaches maximum intensity within 10 to 20 minutes. One characteristic of the pain that is present in about one-half of patients and suggests a pancreatic origin is band-like radiation to the back. Painless disease is uncommon (5 to 10 percent) but may be complicated and fatal.",
"   </p>",
"   <p>",
"    The abdominal pain is typically accompanied (approximately 90 percent) by nausea and vomiting that may persist for many hours. Restlessness, agitation, and relief on bending forward are other notable symptoms. Patients with fulminant attacks may present in shock or coma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dyspepsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An international committee of clinical investigators developed the following definition (Rome criteria) of dyspepsia for research purposes, which can also be applied to clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;\"Dyspepsia is persistent or recurrent abdominal pain or abdominal discomfort centered in the upper abdomen. Discomfort refers to a subjective, negative feeling that does not reach the level of pain according to the patient. Centering refers to pain or discomfort mainly localized to the upper abdomen; it does not exclude patients who have pain or discomfort elsewhere unless they only have pain elsewhere.\"",
"   </p>",
"   <p>",
"    The differential diagnosis of dyspepsia includes gastroesophageal reflux disease, peptic ulcer disease, biliary disease, irritable bowel syndrome, chronic pancreatitis, gastric cancer, drug-induced dyspepsia, psychiatric disease, diabetic gastroparesis, metabolic diseases, gastrointestinal and pancreatic malignancies, ischemic heart disease, and abdominal wall pain. A detailed description of a patient with these syndromes is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=see_link\">",
"     \"Approach to the patient with dyspepsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hiatus hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both sliding and paraesophageal hernias can occasionally become incarcerated and cause severe chest and epigastric pain requiring emergency surgery. Hiatal hernias may also develop following surgery that involves the diaphragm, including partial gastrectomy, fundoplication, and bariatric surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7527?source=see_link\">",
"     \"Hiatus hernia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumonia involving the lower lobes of the lung is a common cause of abdominal pain syndromes, presumably related to diaphragmatic irritation, and may be confused with acute cholecystitis or, rarely, an acute abdomen. Abdominal pain is occasionally the sole presenting complaint in a patient with lower-lobe pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper abdominal pain can be the presenting symptom of an acute myocardial infarction. Any patient with cardiac risk factors should have an electrocardiogram.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Splenic abscess or infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left upper quadrant pain often arises from diseases of the spleen (",
"    <a class=\"graphic graphic_table graphicRef70233 \" href=\"UTD.htm?19/9/19613\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\", section on 'Splenic abscess'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link&amp;anchor=H8#H8\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\", section on 'Splenic infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Splenic abscesses typically are associated with fever and tenderness in the left upper quadrant and may also be associated with splenic infarction.",
"     </li>",
"     <li>",
"      Splenic infarction also presents with severe left upper quadrant pain. This syndrome should be considered in any patient with atrial fibrillation or other conditions associated with peripheral embolism [",
"      <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/18\">",
"       18",
"      </a>",
"      ]. Other causes of splenic infarction include trauma, torsion due to a \"wandering spleen\" (see",
"      <a class=\"local\" href=\"#H40\">",
"       'Wandering spleen syndrome'",
"      </a>",
"      below), presence of a hypercoagulable state, hemoglobinopathies (see",
"      <a class=\"local\" href=\"#H36\">",
"       'Sickle cell disease'",
"      </a>",
"      below), and a number of other hematologic disorders (eg, polycythemia vera, essential thrombocythemia, myeloid metaplasia) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/19-21\">",
"       19-21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LOWER ABDOMINAL PAIN SYNDROMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Appendicitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute appendicitis is a major consideration in the assessment of any patient with acute abdominal disease. Acute appendicitis typically presents with periumbilical pain initially that radiates to the right lower quadrant; however, occasional patients present with epigastric or generalized abdominal pain. The pain localizes to the right lower quadrant when the appendiceal inflammation begins to involve the peritoneal surface. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31370?source=see_link\">",
"     \"Acute appendicitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Diverticular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncomplicated diverticulosis is often asymptomatic and an incidental finding on colonoscopy or sigmoidoscopy. Some of these patients complain of symptoms such as cramping, bloating, flatulence, and irregular defecation. Diverticulitis represents microscopic or macroscopic perforation of a diverticulum.",
"   </p>",
"   <p>",
"    The clinical presentation of diverticulitis depends upon the severity of the underlying inflammatory process and whether or not complications are present. Left lower quadrant pain is the most common complaint in Western countries, occurring in 70 percent of patients. Right-sided diverticulitis occurs in only 1.5 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/22\">",
"     22",
"    </a>",
"    ]. In contrast, right-sided disease is more common in Asians (accounting for as many as 75 percent of cases of diverticulitis), and affected patients may present with right lower quadrant pain, often leading to a misdiagnosis of acute appendicitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34919?source=see_link\">",
"     \"Clinical manifestations and diagnosis of colonic diverticular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pain is often present for several days prior to presentation, which aids in the differentiation of diverticulitis from other causes of acute abdominal symptoms. Only 17 percent in one series had symptoms for less than 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/25\">",
"     25",
"    </a>",
"    ]. Another helpful diagnostic finding is that up to one-half have had one or more previous episodes of similar pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34919?source=see_link\">",
"     \"Clinical manifestations and diagnosis of colonic diverticular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Kidney stones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kidney stones usually cause symptoms when the stone passes from the renal pelvis into the ureter. Pain is the most common symptom and varies from a mild and barely noticeable ache, to discomfort that is so intense it requires hospitalization and parenteral medications. The pain typically waxes and wanes in severity and develops in waves or paroxysms that are related to movement of the stone in the ureter and to associated ureteral spasm. Paroxysms of severe pain usually last 20 to 60 minutes.",
"   </p>",
"   <p>",
"    The site of obstruction determines the location of pain. Upper ureteral or renal pelvic obstruction lead to flank pain or tenderness, whereas lower ureteral obstruction causes pain that may radiate to the ipsilateral testicle, tip of the penis, or labia. The location of the pain may change as the stone migrates; a variable location of pain can be misleading and occasionally mimics an acute abdomen or dissecting aneurysm. In addition, some patients present with abdominal pain in the absence of flank pain. CT scan is the gold standard to confirm the diagnosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69052 \" href=\"UTD.htm?10/21/10577\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=see_link\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Bladder distension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with bladder outlet obstruction leading to acute bladder distension, as may occur in some patients with benign prostatic hypertrophy, can present with lower abdominal pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pelvic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower abdominal pain in women is frequently due to disorders of the reproductive organs. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Women'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFUSE ABDOMINAL PAIN SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse abdominal pain syndromes often represent severe and potentially life-threatening disease. Examples include mesenteric ischemia and infarction, ruptured abdominal aortic aneurysm, and diffuse peritonitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Mesenteric ischemia and infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesenteric infarction presents with the acute and severe onset of diffuse and persistent abdominal pain, while chronic mesenteric ischemia may be manifested by a variety of symptoms including abdominal pain after eating (\"intestinal angina\"), weight loss, nausea, vomiting, and diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/26\">",
"     26",
"    </a>",
"    ]. Ischemia that involves the celiac territory causes epigastric or right upper quadrant pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44377?source=see_link\">",
"     \"Acute mesenteric ischemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33206?source=see_link\">",
"     \"Chronic mesenteric ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mesenteric ischemia and infarction are important considerations in older adult patients presenting with acute abdominal pain and in all patients with acute diffuse abdominal pain. These disorders are thought to occur in up to 1 to 2 percent of all patients presenting with severe acute gastrointestinal illness [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/26\">",
"     26",
"    </a>",
"    ]. Infarction typically occurs in patients with known cardiovascular, ischemic, or arteriosclerotic disease. Mesenteric ischemia may be a manifestation of systemic vasculitis involving the gastrointestinal tract (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24968?source=see_link\">",
"     \"Gastrointestinal manifestations of vasculitis\"",
"    </a>",
"    ). Mesenteric venous thrombosis rarely is a cause of abdominal pain and may occur in previously healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Angiography or MRI angiography of the celiac artery or mesenteric vessels are the diagnostic tests of choice. Sigmoidoscopy can also suggest the diagnosis in patients with ischemic colitis but is usually not required (",
"    <a class=\"graphic graphic_picture graphicRef59803 \" href=\"UTD.htm?5/12/5316\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/20/42313?source=see_link\">",
"     \"Colonic ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Ruptured aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;A ruptured abdominal aortic aneurysm can present with diffuse or localized abdominal symptoms and can mimic other acute conditions such as renal colic, diverticulitis, pancreatitis, inferior wall coronary ischemia, mesenteric ischemia, or biliary tract disease.",
"   </p>",
"   <p>",
"    The patient with a ruptured abdominal aortic aneurysm who survives long enough to reach the emergency department classically presents with abdominal or back pain, hypotension, and a pulsatile abdominal mass. Aneurysm rupture typically causes exsanguinating hemorrhage and profound, unstable hypotension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with peritonitis attempt to minimize abdominal pain by lying still, often in a supine position with the knees flexed. The pain may be greatest over the region of the abdomen near the abdominal viscera from which the pain originated (as in acute cholecystitis) but may spread rapidly to involve the entire abdomen as inflammation progresses.",
"   </p>",
"   <p>",
"    Physical examination may reveal fever and evidence for hypovolemia (tachycardia and hypotension). Abdominal examination should be performed gently, since it can worsen pain. It is usually unnecessary to elicit rebound tenderness (sudden severe pain caused by rapid release of the hand following abdominal palpation), since peritonitis can usually be suspected from more gentle palpation. A similar approach (elicitation of pain after bumping against the bed) is also usually unnecessary. Abdominal wall rigidity (involuntary guarding) may be present due to activation of primary afferent visceral and cutaneous pain receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Intestinal obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe, acute diffuse abdominal pain can be caused by either partial or complete obstruction of the intestines. The most common causes in adults are an incarcerated hernia, adhesions, intussusception, and volvulus; these syndromes account for as many as 96 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/29\">",
"     29",
"    </a>",
"    ]. Occasionally, severe constipation leading to fecal impaction can cause large bowel obstruction as can an obstructing colonic carcinoma. Celiac disease occasionally manifests itself with an intussusception [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/30\">",
"     30",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Intestinal obstruction should be considered when the patient complains of pain, vomiting, and constipation. Physical findings of abdominal distention and tenderness to palpation are common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ABDOMINAL PAIN IN SPECIAL POPULATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special populations of patients, including women, older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/31\">",
"     31",
"    </a>",
"    ], patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/32\">",
"     32",
"    </a>",
"    ], hemophiliacs, and patients with sickle cell disease, may present with unusual causes of abdominal pain or may have unusual presentations of common disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower abdominal pain (pelvic pain) in women is frequently caused by disorders of the internal female reproductive organs. The major etiologies of acute pain are: pelvic inflammatory disease; adnexal cysts or masses with bleeding, torsion, or rupture; ectopic pregnancy; and uterine pain due to infection (endomyometritis) or due to degeneration, infarction, or torsion of leiomyomas. Chronic pelvic pain in women is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=see_link\">",
"     \"Causes of chronic pelvic pain in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Pelvic inflammatory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower abdominal pain is the cardinal presenting symptom in women with pelvic inflammatory disease (PID), although the character of the pain may be quite subtle. Recent onset of pain that occurs during menses or coitus or with jarring movement may be the only presenting symptom of PID; the new onset of pain during or shortly after menses is particularly suggestive [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/33\">",
"     33",
"    </a>",
"    ]. The abdominal pain is usually bilateral and rarely of more than two to three weeks duration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fever is present in 50 percent, and abnormal uterine bleeding occurs in one-third of patients with PID [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/35\">",
"     35",
"    </a>",
"    ]. New vaginal discharge, urethritis, proctitis, and chills can be associated signs but are neither sensitive nor specific for the diagnosis. The presence of PID is less likely if symptoms referable to the bowel or urinary tract predominate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Adnexal pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cysts and neoplasms of the ovary, fallopian tube, or paraovarian or paratubal areas can cause pain due to rupture, bleeding, or torsion (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23690?source=see_link\">",
"     \"Ovarian and fallopian tube torsion\"",
"    </a>",
"    ). Large size alone, even with compression of adjacent structures, usually does not result in acute pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link\">",
"     \"Approach to the patient with an adnexal mass\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=see_link\">",
"     \"Differential diagnosis of the adnexal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The new onset of mid-cycle pain in premenopausal women suggests the presence of a physiologic cyst (follicular or corpus luteum).",
"     </li>",
"     <li>",
"      Pain immediately following intercourse is suggestive of a ruptured cyst.",
"     </li>",
"     <li>",
"      The sudden onset of severe pain, often associated with nausea and vomiting, is suggestive of ovarian torsion or a degenerating leiomyoma. Acute severe pain simulating appendicitis or peritonitis may also result from perforation, infarction, or hemorrhage into or from an ovarian neoplasm.",
"     </li>",
"     <li>",
"      Pain accompanied by fever suggests an infection such as PID, appendicitis, or diverticulitis, but it may be associated with torsion (ovary or leiomyoma) or degeneration (leiomyoma).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Endometriosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common symptoms of endometriosis include chronic pelvic pain (which is often more severe during menses), dysmenorrhea, dyspareunia, abnormal menstrual bleeding, and infertility. Acute pain, however, may occur due to rupture of an endometrioma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of endometriosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=see_link\">",
"     \"Causes of chronic pelvic pain in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Ectopic pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal pain, menstrual cycle abnormalities (missed or late menstrual period), and vaginal bleeding are the classic symptoms of ectopic pregnancy. Clinical manifestations typically appear six to eight weeks after the last normal menstrual period, but they can occur later. Vital signs may reveal orthostatic changes and, occasionally, fever. Findings on physical examination may include adnexal, cervical motion,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abdominal tenderness, an adnexal mass, and mild uterine enlargement. However, the physical examination is often unremarkable in a woman with a small, unruptured ectopic pregnancy. A sensitive test for human chorionic gonadotropin will always be positive and serves to distinguish ectopic pregnancy from other causes of lower abdominal pain in women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Endometritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometritis refers to inflammation of the endometrium, the inner lining of the uterus. It is characterized by uterine pain, vaginal bleeding, and fever. Sexually transmitted infections and invasive gynecologic procedures are the most common predecessors of acute endometritis in the nonobstetric population. Postpartum infection, usually after a labor concluded by cesarean delivery or after prolonged labor or rupture of membranes with multiple vaginal examinations, is the most frequent antecedent of acute endometritis in the obstetric population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39097?source=see_link\">",
"     \"Postpartum endometritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Leiomyomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leiomyomas (fibroids) infrequently cause acute pain from degeneration (eg, carneous or red degeneration) or torsion of a pedunculated tumor. Pain may be associated with a low grade fever, uterine tenderness on palpation, elevated white blood cell count, or peritoneal signs. The discomfort resulting from degenerating leiomyomas is self-limited, lasting from days to a few weeks, and it usually responds to nonsteroidal antiinflammatory drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older adult patients often do not present with the same signs and symptoms of disease characteristic of younger individuals. This was illustrated in a retrospective review of 231 patients over the age of 64 who presented to an emergency department with acute (less than one week) nontraumatic abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/36\">",
"     36",
"    </a>",
"    ]. The presence or absence of abnormal test values (hemoglobin, alkaline phosphatase, aspartate aminotransferase, bilirubin, lactate, and leukocytosis) did not distinguish those who were admitted and did not require surgery from patients with surgical disease; clinical suspicion was a more important distinguishing feature. Normal laboratory tests at presentation occurred in 13 percent of patients who ultimately required surgery. Biliary tract disease and small bowel obstruction were common disorders in older patients presenting with acute abdominal pain.",
"   </p>",
"   <p>",
"    In a second review of 168 older adult patients presenting to an emergency department with acute cholecystitis (confirmed later by surgery), 84 percent had neither epigastric nor right upper quadrant pain, and 5 percent had no pain at all [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/37\">",
"     37",
"    </a>",
"    ]. Common presenting symptoms were nausea (57 percent) and vomiting (38 percent). Many patients were afebrile (56 percent), and 13 percent had no fever and normal laboratory studies.",
"   </p>",
"   <p>",
"    Common causes of abdominal pain in older persons include appendicitis, aneurysmal disease, mesenteric ischemia, diverticulitis, and small bowel obstruction. The frequency of misdiagnosis of the acute abdomen in older patients is high and associated with higher mortality rates than in younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal and hepatobiliary symptoms are among the most frequent complaints in patients with human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS). The frequency of abdominal pain as a symptom in patients with AIDS is unknown; however, acute abdominal pain is often a serious finding. In the majority of patients with AIDS, abdominal pain is directly related to HIV and its consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/39\">",
"     39",
"    </a>",
"    ], but the more common causes of abdominal pain in the general population also need to be considered. Many studies of abdominal pain in patients with AIDS stress the broad spectrum of potential causes for this symptom (",
"    <a class=\"graphic graphic_table graphicRef67173 \" href=\"UTD.htm?37/57/38812\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Hemophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemophiliacs may spontaneously develop hematomas of the bowel wall, which can cause symptoms that mimic acute appendicitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/41\">",
"     41",
"    </a>",
"    ]. The diagnosis of \"pseudo-appendicitis\" can usually be made with CT imaging; at times, surgery is required to confirm the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Sickle cell disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with sickle cell disease may have abdominal pain as part of a vasoocclusive crisis. Such pain may be difficult to distinguish from an acute surgical abdomen (eg, appendicitis, cholecystitis) and may be due to such conditions as cholelithiasis, splenic infarction, pancreatitis, ischemic colitis, and nonsurgical genitourinary disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/42-45\">",
"     42-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Right upper quadrant symptoms are common in the setting of hepatic involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/49/2842?source=see_link&amp;anchor=H13#H13\">",
"     \"Hepatic manifestations of sickle cell disease\", section on 'Acute sickle hepatic crisis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H371937548\">",
"    <span class=\"h2\">",
"     Chronic narcotic users",
"    </span>",
"    &nbsp;&mdash;&nbsp;With increasing use of narcotics for chronic pain syndromes, the narcotic bowel syndrome has been recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. This syndrome is characterized by chronic or intermittent abdominal pain, bloating, abdominal distention, and occasional vomiting in patients on chronic or escalating doses of opiates. Relief occurs when the narcotics are gradually withdrawn, though there is a high rate of recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H783431210\">",
"    <span class=\"h2\">",
"     High-dose glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving high-dose glucocorticoids are at an increased risk of bowel perforation and peritonitis. Clinical presentation is often nonspecific, and thus a high level of clinical suspicion and aggressive diagnostic evaluation should be performed when a patient taking glucocorticoids presents with new abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H783431252\">",
"    <span class=\"h1\">",
"     RARE CAUSES OF ABDOMINAL PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare causes of abdominal pain should be considered in the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with repeated visits to physicians or emergency departments for the same complaint without a definite diagnosis",
"     </li>",
"     <li>",
"      An ill appearing patient with minimal or nonspecific findings",
"     </li>",
"     <li>",
"      Pain out of proportion to clinical findings",
"     </li>",
"     <li>",
"      Immunocompromised, HIV-infected, or older patients (see above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Celiac artery compression syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The celiac artery compression syndrome is a rare condition that typically occurs in otherwise healthy young and middle-aged individuals. It presents as chronic, epigastric abdominal pain that typically occurs after eating and may be associated with an epigastric bruit and weight loss. The diagnosis is suggested by narrowing or occlusion of the celiac axis on angiography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/43/27316?source=see_link\">",
"     \"Celiac artery compression syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Painful rib syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The painful rib syndrome is an increasingly common condition characterized by discomfort in the lower chest or upper abdomen, tenderness over the costal margins, and reproduction of the pain by pressure on the ribs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/51\">",
"     51",
"    </a>",
"    ]. This syndrome accounts for as many as 3 percent of new referrals to surgeons for the evaluation of upper abdominal pain. It is most common in women. The syndrome has a benign outcome and is important to recognize and diagnose to avoid unnecessary testing and treatment and to provide reassurance to the patient. In one review, 8 of 76 patients underwent noncurative cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Wandering spleen syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The wandering spleen syndrome is a rare cause of acute abdominal pain that is most typically seen in younger adolescents and children, although it can occur in adults. Patients typically present with acute left upper quadrant pain associated with an abdominal mass. CT imaging confirms the diagnosis. Ultrasound has also been helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/52\">",
"     52",
"    </a>",
"    ]. The treatment of choice is splenopexy; splenectomy may be required if the spleen is infarcted and there is torsion and absence of splenic blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Abdominal wall pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain emanating from the abdominal wall may be difficult to distinguish from deep visceral pain. The pain can originate from a hernia, hematoma, or the abdominal wall musculature. Abdominal wall hernias can be difficult to diagnosis clinically, and CT scan of the abdomen and the abdominal wall are often required. Hematomas of the abdominal wall occur spontaneously or after unrecognized trauma. Abdominal pain originating from the abdominal musculature can be diagnosed by finding a focal area of abdominal tenderness that remains unchanged or increases with abdominal muscle contraction (Carnett's sign). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31030?source=see_link\">",
"     \"Chronic abdominal wall pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Abdominal migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent abdominal pain may occur in patients with abdominal migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/54\">",
"     54",
"    </a>",
"    ]. These patients usually also suffer from typical migraine headaches, although occasional patients present with gastrointestinal symptoms only [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/55\">",
"     55",
"    </a>",
"    ]. Abdominal migraine is much more common during childhood and adolescence. This is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=see_link&amp;anchor=H12#H12\">",
"     \"Classification of migraine in children\", section on 'Abdominal migraine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/17/1306?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation of the child and adolescent with chronic abdominal pain\", section on 'Abdominal migraine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34568?source=see_link\">",
"     \"Cyclic vomiting syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H685316126\">",
"    <span class=\"h2\">",
"     Mesenteric lymphadenitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesenteric lymphadenitis is a cause of lower abdominal pain that can be confused with appendicitis. It is defined radiologically when a cluster of three or more lymph nodes measuring 5 mm or greater are seen [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The etiology is usually infectious (eg, Y. enterocolitica, M. tuberculosis, Salmonella species), malignant, or autoimmune. Mesenteric lymphadenitis may also be seen incidentally on abdominal CT scan. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/63/41974?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Yersinia infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Eosinophilic gastroenteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilic gastroenteritis is a rare condition that may present with variable symptoms including abdominal pain, nausea, vomiting, and diarrhea. The signs and symptoms are related to the layer(s) and extent of bowel involved with eosinophilic infiltration: mucosa, muscle,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subserosa [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/58\">",
"     58",
"    </a>",
"    ]. The diagnosis is suspected in patients with abdominal pain, diarrhea, and peripheral eosinophilia; it may be confused with the irritable bowel syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=see_link\">",
"     \"Eosinophilic gastroenteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Epiploic appendagitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epiploic appendagitis is a benign and self-limited condition of the epiploic appendages that occurs secondary to torsion or spontaneous venous thrombosis of a draining vein [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/59\">",
"     59",
"    </a>",
"    ]. Patients most commonly present with acute abdominal pain. Symptoms can mimic an acute abdomen, frequently leading patients to be misdiagnosed as having acute appendicitis or diverticulitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35076?source=see_link\">",
"     \"Epiploic appendagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Abdominal compartment syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal compartment syndrome should be considered when severe abdominal pain with abdominal distension occurs in someone who has suffered trauma or is experiencing unusual abdominal pain post operatively. The syndrome is lethal if not diagnosed early. Findings noted on CT imaging are bowel wall thickening, elevated diaphragm, and collapse of the inferior vena cava along with mucosal hyperenhancement and hemoperitoneum [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Fitz-Hugh-Curtis syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Fitz-Hugh-Curtis syndrome, or perihepatitis, is a cause of right upper quadrant pain in young women. It occurs in approximately 10 percent of patients with pelvic inflammatory disease caused by Chlamydia trachomatis or Neisseria gonorrhoeae. Physical examination typically reveals marked right upper quadrant tenderness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Familial Mediterranean fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical manifestations of familial Mediterranean fever are recurrent attacks of severe pain (due to serositis at one or more sites) and fever, lasting one to three days and then resolving spontaneously. In between attacks, patients feel entirely well. Pain and fever are usually abrupt and reach their peak soon after onset, although some patients tend to have a stereotypic, mild prodrome component of their attacks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25078?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial Mediterranean fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Hereditary angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary angioedema (HAE) is a disease that arises from abnormal activation of the complement-mediated inflammatory pathways and can present with recurrent episodes of abdominal pain, accompanied by nausea, vomiting, colicky pain, and diarrhea. It most often presents in adolescence, but occurs as well in children and adults. HAE results from defects in the C1 inhibitor of the classical complement pathway.",
"   </p>",
"   <p>",
"    Patients may have a history of intermittent swelling of other tissues (face and hands are common) and can experience life-threatening laryngeal swelling. There may be a family history of similar symptoms. Episodes of abdominal pain resolve spontaneously in two to four days. The diagnosis is made by the demonstration of a low C4 level and low C1 inhibitor antigenic levels or functional levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=see_link\">",
"     \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one series of over 33,000 cases of recurrent abdominal pain, 153 patients were identified with HAE [",
"    <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/61\">",
"     61",
"    </a>",
"    ]. These patient had a high likelihood of also having diarrhea and vomiting. Rarely, these patients presented with circulatory collapse and loss of consciousness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal pain can be caused by myriad illnesses. These may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metabolic disorders ranging from diabetic ketoacidosis to acute intermittent porphyria (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute intermittent porphyria\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Abdominal malignancies (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=see_link\">",
"       \"Overview of cancer pain syndromes\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lactose intolerance (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link\">",
"       \"Lactose intolerance\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Helminthic and other tropical infectious diseases",
"     </li>",
"     <li>",
"      Functional disorders (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=see_link\">",
"       \"Clinical manifestations and diagnosis of irritable bowel syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35272?source=see_link\">",
"       \"Functional dyspepsia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Psychogenic etiologies (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link\">",
"       \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Aortic dissection involving the descending aorta (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"       \"Clinical manifestations and diagnosis of aortic dissection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Systemic vasculitis, which can lead to mesenteric ischemia (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Mesenteric ischemia and infarction'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      ACE inhibitor therapy can cause a visceral form of angioedema and present with recurrent episodes of abdominal pain [",
"      <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/62,63\">",
"       62,63",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mesenteric panniculitis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/30/16874/abstract/64\">",
"       64",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/48/8962?source=see_link\">",
"       \"Patient information: Acute abdomen (belly pain) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/24/5506?source=see_link\">",
"       \"Patient information: Upset stomach (functional dyspepsia) in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/55/32627?source=see_link\">",
"       \"Patient information: Chronic pelvic pain in women (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal pain typically, but not always, has characteristic locations: right upper, right lower, epigastric, periumbilical, left upper, left lower, and diffuse (",
"      <a class=\"graphic graphic_table graphicRef70233 \" href=\"UTD.htm?19/9/19613\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Upper abdominal pain syndromes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Lower abdominal pain syndromes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Diffuse abdominal pain syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain originating in the viscera may also be perceived as originating from a site distant from the affected organ (",
"      <a class=\"graphic graphic_figure graphicRef61375 \" href=\"UTD.htm?23/54/24419\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Referred pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Special populations of patients, including women, older adults, patients with AIDS, hemophiliacs, and patients with sickle cell disease, may present with unusual causes of abdominal pain or may have unusual presentations of common disorders. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Abdominal pain in special populations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rare causes of abdominal pain should be considered in patients with repeated visits for the same complaint without a definite diagnosis, an ill appearing patient with minimal or nonspecific findings, patients with pain out of proportion to clinical findings, and in immunocompromised patients. (See",
"      <a class=\"local\" href=\"#H783431252\">",
"       'Rare causes of abdominal pain'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/1\">",
"      Yamamoto W, Kono H, Maekawa M, Fukui T. The relationship between abdominal pain regions and specific diseases: an epidemiologic approach to clinical practice. J Epidemiol 1997; 7:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/2\">",
"      Ray BS, Neill CL. Abdominal Visceral Sensation in Man. Ann Surg 1947; 126:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/3\">",
"      Cervero F. Neurophysiology of gastrointestinal pain. Baillieres Clin Gastroenterol 1988; 2:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/4\">",
"      Haupt P, J&auml;nig W, Kohler W. Response pattern of visceral afferent fibres, supplying the colon, upon chemical and mechanical stimuli. Pflugers Arch 1983; 398:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/5\">",
"      Bentley FH. Observations on Visceral Pain : (1) Visceral Tenderness. Ann Surg 1948; 128:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/6\">",
"      Whitehead WE, Holtkotter B, Enck P, et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990; 98:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/7\">",
"      CHAPMAN WP, HERRERA R, JONES CM. A comparison of pain produced experimentally in lower esophagus, common bile duct, and upper small intestine with pain experienced by patients with diseases of biliary tract and pancreas. Surg Gynecol Obstet 1949; 89:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/8\">",
"      Brown FR. The Problem of Abdominal Pain. Br Med J 1942; 1:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/9\">",
"      Bloomfield AL, Polland WS. EXPERIMENTAL REFERRED PAIN FROM THE GASTRO-INTESTINAL TRACT. PART II. STOMACH, DUODENUM AND COLON. J Clin Invest 1931; 10:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/10\">",
"      DWORKEN HJ, BIEL FJ, MACHELLA TE. Supradiaphragmatic reference of pain from the colon. Gastroenterology 1952; 22:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/11\">",
"      Ryle JA. Visceral pain and referred pain. Lancet 1926; 1:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/12\">",
"      Selzer M, Spencer WA. Convergence of visceral and cutaneous afferent pathways in the lumbar spinal cord. Brain Res 1969; 14:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/13\">",
"      Purcell TB. Nonsurgical and extraperitoneal causes of abdominal pain. Emerg Med Clin North Am 1989; 7:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/14\">",
"      Saik RP, Greenburg AG, Farris JM, Peskin GW. Spectrum of cholangitis. Am J Surg 1975; 130:143.",
"     </a>",
"    </li>",
"    <li>",
"     Go VL, Everhart JE. Pancreatitis. In: Digestive diseases in the United States: Epidemiology and impact, Everhart JE (Ed), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. US Government Printing Office, Washington, DC 1994. p.693.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/16\">",
"      Talley NJ, Colin-Jones D, Koch KL, et al. Functional dyspepsia: A classification with guidelines for diagnosis and management. Gastroenterol Int 1992; 4:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/17\">",
"      Flanagin BA, Mitchell MT, Thistlethwaite WA, Alverdy JC. Diagnosis and treatment of atypical presentations of hiatal hernia following bariatric surgery. Obes Surg 2010; 20:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/18\">",
"      Beeson MS. Splenic infarct presenting as acute abdominal pain in an older patient. J Emerg Med 1996; 14:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/19\">",
"      Nores M, Phillips EH, Morgenstern L, Hiatt JR. The clinical spectrum of splenic infarction. Am Surg 1998; 64:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/20\">",
"      Franklin QJ, Compeggie M. Splenic syndrome in sickle cell trait: four case presentations and a review of the literature. Mil Med 1999; 164:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/21\">",
"      G&ouml;rg C, Seifart U, G&ouml;rg K. Acute, complete splenic infarction in cancer patient is associated with a fatal outcome. Abdom Imaging 2004; 29:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/22\">",
"      Fischer MG, Farkas AM. Diverticulitis of the cecum and ascending colon. Dis Colon Rectum 1984; 27:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/23\">",
"      Sugihara K, Muto T, Morioka Y, et al. Diverticular disease of the colon in Japan. A review of 615 cases. Dis Colon Rectum 1984; 27:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/24\">",
"      Ngoi SS, Chia J, Goh MY, et al. Surgical management of right colon diverticulitis. Dis Colon Rectum 1992; 35:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/25\">",
"      Rodkey GV, Welch CE. Changing patterns in the surgical treatment of diverticular disease. Ann Surg 1984; 200:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/26\">",
"      Schneider TA, Longo WE, Ure T, Vernava AM 3rd. Mesenteric ischemia. Acute arterial syndromes. Dis Colon Rectum 1994; 37:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/27\">",
"      Mock JN, Orsay EM. Primary mesenteric venous thrombosis: an unusual cause of abdominal pain in a young, healthy woman. Ann Emerg Med 1994; 23:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/28\">",
"      Selzer M, Spencer WA. Interactions between visceral and cutaneous afferents in the spinal cord: reciprocal primary afferent fiber depolarization. Brain Res 1969; 14:349.",
"     </a>",
"    </li>",
"    <li>",
"     Silen W. Cope's Early Diagnosis of the Acute Abdomen. In: Cope's Early Diagnosis of the Acute Abdomen, Oxford University Press, Oxford 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/30\">",
"      Gonda TA, Khan SU, Cheng J, et al. Association of intussusception and celiac disease in adults. Dig Dis Sci 2010; 55:2899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/31\">",
"      de Dombal FT. Acute abdominal pain in the elderly. J Clin Gastroenterol 1994; 19:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/32\">",
"      Thuluvath PJ, Connolly GM, Forbes A, Gazzard BG. Abdominal pain in HIV infection. Q J Med 1991; 78:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/33\">",
"      Korn AP, Hessol NA, Padian NS, et al. Risk factors for plasma cell endometritis among women with cervical Neisseria gonorrhoeae, cervical Chlamydia trachomatis, or bacterial vaginosis. Am J Obstet Gynecol 1998; 178:987.",
"     </a>",
"    </li>",
"    <li>",
"     Westrom L, Mardh PA. Epidemiology, etiology, and prognosis of acute salpingitis: A study of 1,457 laparoscopically verified cases. In: Nongonococcal Urethritis and Related Diseases, Hobson D, Holmes KK (Eds), Am Soc Microbiol, Washington, DC 1977. p.84.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/35\">",
"      Jacobson L, Westr&ouml;m L. Objectivized diagnosis of acute pelvic inflammatory disease. Diagnostic and prognostic value of routine laparoscopy. Am J Obstet Gynecol 1969; 105:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/36\">",
"      Bugliosi TF, Meloy TD, Vukov LF. Acute abdominal pain in the elderly. Ann Emerg Med 1990; 19:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/37\">",
"      Parker LJ, Vukov LF, Wollan PC. Emergency department evaluation of geriatric patients with acute cholecystitis. Acad Emerg Med 1997; 4:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/38\">",
"      Lyon C, Clark DC. Diagnosis of acute abdominal pain in older patients. Am Fam Physician 2006; 74:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/39\">",
"      Parente F, Cernuschi M, Antinori S, et al. Severe abdominal pain in patients with AIDS: frequency, clinical aspects, causes, and outcome. Scand J Gastroenterol 1994; 29:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/40\">",
"      Ferguson CM. Surgical complications of human immunodeficiency virus infection. Am Surg 1988; 54:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/41\">",
"      McCoy HE 3rd, Kitchens CS. Small bowel hematoma in a hemophiliac as a cause of pseudoappendicitis: diagnosis by CT imaging. Am J Hematol 1991; 38:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/42\">",
"      Baumgartner F, Klein S. The presentation and management of the acute abdomen in the patient with sickle-cell anemia. Am Surg 1989; 55:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/43\">",
"      Jama AH, Salem AH, Dabbous IA. Massive splenic infarction in Saudi patients with sickle cell anemia: a unique manifestation. Am J Hematol 2002; 69:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/44\">",
"      Karim A, Ahmed S, Rossoff LJ, et al. Fulminant ischaemic colitis with atypical clinical features complicating sickle cell disease. Postgrad Med J 2002; 78:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/45\">",
"      Ahmed S, Siddiqui AK, Siddiqui RK, et al. Acute pancreatitis during sickle cell vaso-occlusive painful crisis. Am J Hematol 2003; 73:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/46\">",
"      Grunkemeier DM, Cassara JE, Dalton CB, Drossman DA. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol 2007; 5:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/47\">",
"      Drossman DA, Morris CB, Edwards H, et al. Diagnosis, characterization, and 3-month outcome after detoxification of 39 patients with narcotic bowel syndrome. Am J Gastroenterol 2012; 107:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/48\">",
"      ReMine SG, McIlrath DC. Bowel perforation in steroid-treated patients. Ann Surg 1980; 192:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/49\">",
"      Menegaux F, Chenard X, Wechsler B, et al. Diffuse peritonitis in steroid-treated patients. Dig Surg 1998; 15:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/50\">",
"      Pearigen PD. Unusual causes of abdominal pain. Emerg Med Clin North Am 1996; 14:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/51\">",
"      Scott EM, Scott BB. Painful rib syndrome--a review of 76 cases. Gut 1993; 34:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/52\">",
"      Karmazyn B, Steinberg R, Gayer G, et al. Wandering spleen--the challenge of ultrasound diagnosis: report of 7 cases. J Clin Ultrasound 2005; 33:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/53\">",
"      Hussain M, Deshpande R, Bailey ST. Splenic torsion: a case report. Ann R Coll Surg Engl 2010; 92:W51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/54\">",
"      Roberts JE, deShazo RD. Abdominal migraine, another cause of abdominal pain in adults. Am J Med 2012; 125:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/55\">",
"      d'Onofrio F, Cologno D, Buzzi MG, et al. Adult abdominal migraine: a new syndrome or sporadic feature of migraine headache? A case report. Eur J Neurol 2006; 13:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/56\">",
"      Rao PM, Rhea JT, Novelline RA. CT diagnosis of mesenteric adenitis. Radiology 1997; 202:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/57\">",
"      Macari M, Hines J, Balthazar E, Megibow A. Mesenteric adenitis: CT diagnosis of primary versus secondary causes, incidence, and clinical significance in pediatric and adult patients. AJR Am J Roentgenol 2002; 178:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/58\">",
"      Klein NC, Hargrove RL, Sleisenger MH, Jeffries GH. Eosinophilic gastroenteritis. Medicine (Baltimore) 1970; 49:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/59\">",
"      Ozdemir S, Gulpinar K, Leventoglu S, et al. Torsion of the primary epiploic appendagitis: a case series and review of the literature. Am J Surg 2010; 199:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/60\">",
"      Patel A, Lall CG, Jennings SG, Sandrasegaran K. Abdominal compartment syndrome. AJR Am J Roentgenol 2007; 189:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/61\">",
"      Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006; 119:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/62\">",
"      Spahn TW, Grosse-Thie W, Mueller MK. Endoscopic visualization of angiotensin-converting enzyme inhibitor-induced small bowel angioedema as a cause of relapsing abdominal pain using double-balloon enteroscopy. Dig Dis Sci 2008; 53:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/63\">",
"      Byrne TJ, Douglas DD, Landis ME, Heppell JP. Isolated visceral angioedema: an underdiagnosed complication of ACE inhibitors? Mayo Clin Proc 2000; 75:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/30/16874/abstract/64\">",
"      Nicholson JA, Smith D, Diab M, Scott MH. Mesenteric panniculitis in Merseyside: a case series and a review of the literature. Ann R Coll Surg Engl 2010; 92:W31.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6860 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_30_16874=[""].join("\n");
var outline_f16_30_16874=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H51\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEUROLOGIC BASIS OF ABDOMINAL PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Localization of pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Referred pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Extra-abdominal causes of abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      UPPER ABDOMINAL PAIN SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Biliary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hiatus hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Splenic abscess or infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LOWER ABDOMINAL PAIN SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Appendicitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Diverticular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Kidney stones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Bladder distension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pelvic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFUSE ABDOMINAL PAIN SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Mesenteric ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Ruptured aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Peritonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Intestinal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ABDOMINAL PAIN IN SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Adnexal pathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Endometriosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Endometritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Leiomyomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Hemophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H371937548\">",
"      Chronic narcotic users",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H783431210\">",
"      High-dose glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H783431252\">",
"      RARE CAUSES OF ABDOMINAL PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Celiac artery compression syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Painful rib syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Wandering spleen syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Abdominal wall pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Abdominal migraine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H685316126\">",
"      Mesenteric lymphadenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Eosinophilic gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Epiploic appendagitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Fitz-Hugh-Curtis syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Hereditary angioedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6860\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6860|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/21/10577\" title=\"diagnostic image 1\">",
"      CT scan showing ureteral stone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6860|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/54/24419\" title=\"figure 1\">",
"      Patterns of referred abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6860|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/12/5316\" title=\"picture 1\">",
"      Ischemic colitis on colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6860|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/9/19613\" title=\"table 1\">",
"      Causes of abdominal pain by location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/4/12365\" title=\"table 2\">",
"      Extra-abdominal causes abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/57/38812\" title=\"table 3\">",
"      Diff dx abd pain in AIDS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31370?source=related_link\">",
"      Acute appendicitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=related_link\">",
"      Acute cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44377?source=related_link\">",
"      Acute mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=related_link\">",
"      Approach to the patient with an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=related_link\">",
"      Approach to the patient with dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=related_link\">",
"      Causes of chronic pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/43/27316?source=related_link\">",
"      Celiac artery compression syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31030?source=related_link\">",
"      Chronic abdominal wall pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33206?source=related_link\">",
"      Chronic mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=related_link\">",
"      Classification of migraine in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=related_link\">",
"      Clinical features and diagnosis of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/63/41974?source=related_link\">",
"      Clinical manifestations and diagnosis of Yersinia infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=related_link\">",
"      Clinical manifestations and diagnosis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34919?source=related_link\">",
"      Clinical manifestations and diagnosis of colonic diverticular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25078?source=related_link\">",
"      Clinical manifestations and diagnosis of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=related_link\">",
"      Clinical manifestations and diagnosis of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=related_link\">",
"      Clinical manifestations and diagnosis of sphincter of Oddi dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/20/42313?source=related_link\">",
"      Colonic ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34568?source=related_link\">",
"      Cyclic vomiting syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=related_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=related_link\">",
"      Differential diagnosis of the adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=related_link\">",
"      Eosinophilic gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35076?source=related_link\">",
"      Epiploic appendagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/17/1306?source=related_link\">",
"      Evaluation of the child and adolescent with chronic abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35272?source=related_link\">",
"      Functional dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24968?source=related_link\">",
"      Gastrointestinal manifestations of vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/49/2842?source=related_link\">",
"      Hepatic manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=related_link\">",
"      Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7527?source=related_link\">",
"      Hiatus hernia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40323?source=related_link\">",
"      History and physical examination in adults with abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=related_link\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23690?source=related_link\">",
"      Ovarian and fallopian tube torsion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=related_link\">",
"      Overview of cancer pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=related_link\">",
"      Pathophysiology and clinical presentation of ischemic chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12697?source=related_link\">",
"      Pathophysiology of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/48/8962?source=related_link\">",
"      Patient information: Acute abdomen (belly pain) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/55/32627?source=related_link\">",
"      Patient information: Chronic pelvic pain in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/24/5506?source=related_link\">",
"      Patient information: Upset stomach (functional dyspepsia) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21608?source=related_link\">",
"      Postherpetic neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39097?source=related_link\">",
"      Postpartum endometritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_30_16875="Distinguishing serotonin and neuroleptic malignant syndromes";
var content_f16_30_16875=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Serotonin syndrome and neuroleptic malignant syndrome: Distinguishing features",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serotonin syndrome (SS)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Neuroleptic malignant syndrome (NMS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Onset",
"       </td>",
"       <td>",
"        Within 24 hours",
"       </td>",
"       <td>",
"        Days to weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuromuscular findings",
"       </td>",
"       <td>",
"        Hyperreactivity (tremor, clonus, reflexes)",
"       </td>",
"       <td>",
"        Bradyreflexia, severe muscular rigidity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Causative agents",
"       </td>",
"       <td>",
"        Serotonin agonist",
"       </td>",
"       <td>",
"        Dopamine antagonist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment agents",
"       </td>",
"       <td>",
"        Benzodiazepine, cyproheptadine",
"       </td>",
"       <td>",
"        Bromocriptine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resolution",
"       </td>",
"       <td>",
"        Within 24 hours",
"       </td>",
"       <td>",
"        Days to weeks",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_30_16875=[""].join("\n");
var outline_f16_30_16875=null;
var title_f16_30_16876="Myelopoiesis knockouts";
var content_f16_30_16876=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F67668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F67668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Phenotypes of mice lacking specific hematopoietic growth factors or growth factor receptors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Phenotype",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Missing hematopoietic growth factor or growth factor receptor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        GM-CSF",
"       </td>",
"       <td>",
"        Normal hematopoiesis and progenitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progressive accumulation of pulmonary surfactant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        G-CSF",
"       </td>",
"       <td>",
"        Circulating neutrophils 25 percent of normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progenitors 50 percent of normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impaired response to Listeria monocytogenes infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        IL-3/GM-CSF/IL-5 (bc) receptor",
"       </td>",
"       <td>",
"        Similar to mice lacking GM-CSF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low eosinophils and impaired eosinophil response to N. brasiliensis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Missing transcription factor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        PU.1",
"       </td>",
"       <td>",
"        Embryonically lethal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absence of granulocytes, monocytes, T and B lymphocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        C/EBP-alpha",
"       </td>",
"       <td>",
"        Death soon after birth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absent neutrophils and eosinophils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impaired glucose metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        C/EBP-beta",
"       </td>",
"       <td>",
"        Defective monocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myelodysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        C/EBP-epsilon",
"       </td>",
"       <td>",
"        Early death from opportunistic infection and myelodysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Specific granule deficiency and abnormal neutrophil function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AML1 or CBF-beta",
"       </td>",
"       <td>",
"        Embryonically lethal due to failure of hematopoiesis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     For references, please refer to the UpToDate topic on the&nbsp;regulation of myelopoiesis.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_30_16876=[""].join("\n");
var outline_f16_30_16876=null;
var title_f16_30_16877="Homesickness prevention for planned separation";
var content_f16_30_16877=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Homesickness-prevention strategies for parents to use with children around planned separations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       1. Discuss the upcoming separation with your child. Young people should be told, \"Almost everyone misses something about home when they are away. Homesickness is normal. And the good news is that there are lots of things you can think and do to help make things better if homesickness bothers you.\"",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Involve your child in the decision to spend time away from home. Prepare and pack as a family. Taking part in even the smallest decisions will increase perceptions of control. By contrast, feeling forced to leave home often increases the severity of homesickness.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       3. Discuss coping strategies with your child. Using some of these strategies during practice time away from home will boost your child's confidence about the separation.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       a. Do something fun, like play with friends, to forget about homesick feelings.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       b. Do something (write a letter, look at a family picture) to feel closer to home.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       c. Go see someone who can talk with you to help you feel better.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       d. Think about the good side of things (activities, friends) to feel better.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       e. Think that time away is actually pretty short to make time go by faster.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       f. Try not to think about home and loved ones to forget about homesickness.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       g. Think about loved ones to figure out what they would say to help.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Arrange for practice time away from home, such as a weekend at a friend's or relative's house. Ideally, these two or three days do not include telephone calls but do include opportunities for writing a letter or postcard home. After the practice time away, discuss with your child how things went and which coping strategies worked best.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Practice correspondence. Ensuring that children know how to write traditional letters increases the likelihood that they will maintain some contact with home. Give children prestamped, preaddressed envelopes and notebook paper.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Work together with your child to learn about their new environment, be it a hospital, school, new neighborhood, or summer camp. The more young people know about the new place to which they are going, the more at home they will feel when they arrive. Web sites, orientation booklets, and current participants, alumni, or staff members are excellent resources.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Help your child get to know some of the people in the new environment. Having at least one familiar face, be it an adult or a peer, in a new place can diminish feelings of homesickness by increasing feelings of social support and connection.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       8. Encourage your child to make new friends and seek the support of trusted adults. Both kinds of connections ease the transition to a new environment.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       9. Avoid expressing anxious or ambivalent feelings about time away from home to your child. Instead, express enthusiasm and optimism about the fun your child is going to have in the new environment.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10. Use a wall calendar to show your child the time between today and the day of the separation. Highlight which days or weeks they will be away so that he or she can see that it is a discrete period, not an eternity. During the separation, a calendar might be a way for your child to keep perspective on the separation.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       11. Do not make a \"pick-up deal\" with your son or daughter. Promising that \"if you don't like it, I'll come pick you up\" decreases your child's likelihood of success in the new environment; this will give the impression to your child that you have so little confidence in his or her ability to cope with the separation that the only solution is to be rescued. Also, such deals create difficulties for staff members, who after enthusiastic support and coaching may be faced with a child who says, \"My parents said that if I didn't like it here, they would come to get me.\" It also puts you in the position of either (1) fulfilling your promise to pick up your child, robbing him or her of a wonderful opportunity to grow and develop, or (2) reneging on your promise, causing an erosion of trust in your relationship with your child. Respond to the query, \"What if I feel homesick?\" with a statement such as, \"You probably will feel a little homesick, but your practice time away has taught you what to think or do in case any homesickness bothers you. Plus, staff members will be there to talk with you and help you make it through. You'll have a great time.\"",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Thurber CA, Walton E, the Council on School Health. Preventing and treating homesickness. Pediatrics 2007; 119:192. Copyright &copy; 2007 by the AAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_30_16877=[""].join("\n");
var outline_f16_30_16877=null;
var title_f16_30_16878="AB subgroups KPD";
var content_f16_30_16878=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F72722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F72722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    A&beta; subgroups of ketosis-prone diabetes mellitus: Clinical characteristics and natural history",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        A+&beta;-",
"       </td>",
"       <td class=\"subtitle1\">",
"        A-&beta;-",
"       </td>",
"       <td class=\"subtitle1\">",
"        A+&beta;+",
"       </td>",
"       <td class=\"subtitle1\">",
"        A-&beta;+",
"       </td>",
"       <td class=\"subtitle1\">",
"        P",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number",
"       </td>",
"       <td>",
"        18 (17 percent)",
"       </td>",
"       <td>",
"        23 (22 percent)",
"       </td>",
"       <td>",
"        11 (11 percent)",
"       </td>",
"       <td>",
"        51 (50 percent)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age",
"       </td>",
"       <td>",
"        34 &plusmn; 17",
"       </td>",
"       <td>",
"        38 &plusmn; 15",
"       </td>",
"       <td>",
"        43 &plusmn; 14",
"       </td>",
"       <td>",
"        42 &plusmn; 13",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age at diagnosis",
"       </td>",
"       <td>",
"        25 &plusmn; 17",
"       </td>",
"       <td>",
"        26 &plusmn; 12",
"       </td>",
"       <td>",
"        42 &plusmn; 12",
"       </td>",
"       <td>",
"        39 &plusmn; 12",
"       </td>",
"       <td>",
"        &lt;0.0001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Years with diabetes",
"       </td>",
"       <td>",
"        9.1 &plusmn; 10.4",
"       </td>",
"       <td>",
"        9.8 &plusmn; 8.7",
"       </td>",
"       <td>",
"        0.9 &plusmn; 3.0",
"       </td>",
"       <td>",
"        3.0 &plusmn; 4.8",
"       </td>",
"       <td>",
"        &lt;0.0001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family history of diabetes",
"       </td>",
"       <td>",
"        9 (50 percent)",
"       </td>",
"       <td>",
"        19 (83 percent)",
"       </td>",
"       <td>",
"        9 (82 percent)",
"       </td>",
"       <td>",
"        45 (88 percent)",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BMI",
"       </td>",
"       <td>",
"        24.5 &plusmn; 3.9",
"       </td>",
"       <td>",
"        23.0 &plusmn; 2.8",
"       </td>",
"       <td>",
"        30.6 &plusmn; 7.6",
"       </td>",
"       <td>",
"        29.4 &plusmn; 8.3",
"       </td>",
"       <td>",
"        0.0003",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Weight category",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &lt;0.0001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lean",
"       </td>",
"       <td class=\"sublist_other\">",
"        11 (61 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        17 (74 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        2 (18 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        17 (33 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Overweight",
"       </td>",
"       <td class=\"sublist_other\">",
"        5 (28 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        6 (26 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        4 (36 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        13 (26 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Obese",
"       </td>",
"       <td class=\"sublist_other\">",
"        2 (11 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        5 (46 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        21 (41 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New onset diabetes",
"       </td>",
"       <td>",
"        3 (17 percent)",
"       </td>",
"       <td>",
"        2 (9 percent)",
"       </td>",
"       <td>",
"        10 (91 percent)",
"       </td>",
"       <td>",
"        26 (51 percent)",
"       </td>",
"       <td>",
"        &lt;0.0001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Male:Female ratio",
"       </td>",
"       <td>",
"        1:1",
"       </td>",
"       <td>",
"        1.3:1",
"       </td>",
"       <td>",
"        0.6:1",
"       </td>",
"       <td>",
"        1.7:1",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Ethnicity",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        0.02",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        African-American",
"       </td>",
"       <td class=\"sublist_other\">",
"        13 (72 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        9 (39 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        4 (36.4 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        14 (27 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hispanic-American",
"       </td>",
"       <td class=\"sublist_other\">",
"        2 (11 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        9 (39 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        4 (36.4 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        30 (59 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Caucasian-American",
"       </td>",
"       <td class=\"sublist_other\">",
"        2 (11 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        5 (22 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        3 (27.2 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        6 (12 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Asian-American",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 (6 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 (2 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent DKA episodes",
"       </td>",
"       <td>",
"        7 (39 percent)",
"       </td>",
"       <td>",
"        7 (30 percent)",
"       </td>",
"       <td>",
"        1 (9 percent)",
"       </td>",
"       <td>",
"        1 (2 percent)",
"       </td>",
"       <td>",
"        &lt;0.0001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insulin discontinued by 6 months",
"       </td>",
"       <td>",
"        0 (0 percent)",
"       </td>",
"       <td>",
"        0 (0 percent)",
"       </td>",
"       <td>",
"        5 (45 percent)",
"       </td>",
"       <td>",
"        26 (51 percent)",
"       </td>",
"       <td>",
"        &lt;0.0001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Anti-diabetic regimen at 12 months",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &lt;0.0001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Insulin only",
"       </td>",
"       <td class=\"sublist_other\">",
"        17 (94 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        23 (100 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        3 (27 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        17 (33 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Insulin + oral hypoglycemics",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 (6 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        3 (27 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        8 (16 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Oral hypoglycemics only",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        3 (27 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        21 (41 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diet and exercise only",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        2 (19 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        5 (10 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Balasubramanyam A, Nalini R, Hampe CS, Maldonado M. Syndromes of Ketosis-Prone Diabetes Mellitus. Endocr Rev 2008; 29:292. Copyright &copy; 2008 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_30_16878=[""].join("\n");
var outline_f16_30_16878=null;
var title_f16_30_16879="Post fossa ependymoma MRI T2";
var content_f16_30_16879=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior fossa ependymoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 317px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A T2 image demonstrating the ependymoma in the posterior fossa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mark Kieran, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_30_16879=[""].join("\n");
var outline_f16_30_16879=null;
